Scientific Programme

Wednesday, 23 May 2018

Others
12:00 - 14:00 Room 1.15

Echocardiography (TEE) course: Transesophageal Echocardiography for Liver Transplantation

Chairs:
Dmitri Bezinover, Hershey, United States
Jeron Zerillo, New York, United States

12:00
Transesophageal Echocardiography for Liver Transplantation
Thomas Verbeek, Hershey, United States
Cindy Wang, New York, United States

Featured Symposium
13:00 - 16:50 Auditorium 8

Post-Graduate Course: Changing scenarios in liver transplantation

Chairs:
Patrizia Burra, Padua, Italy
John Roberts, San Francisco, United States

13:00
Introduction
Patrizia Burra, Padua, Italy

13:15
Session one: Non alcoholic steato-hepatitis
Critical variables in the evaluation of NASH end stage liver disease candidates
Luca Miele, Lazio, Italy

New therapeutic options for NASH and NAFLD to prevent end-stage liver disease
Franck Tacke, Germany

Is there a need to modify immunosuppression regimens in the management of recurrent and de novo NASH after liver transplantation?
Emmanuel Tsochatzis, United Kingdom

14:15
Discussion

14:25
Session 2: Hepatitis B virus-related liver disease
Liver transplantation for acute HBV hepatitis: Déjà vu
Didier Samuel, Villejuif, France

HBsAg and anti-HCV positive donors: Should we push for increased use in deceased and living donor liver transplantation?
Paolo Grossi, Varese, Italy

The role of HBlg in long-term prophylaxis of HBV recurrence
Krzysztof Zieniewicz, Warsaw, Poland
Scientific Programme

**Discussion**

15:25

**Session three: Hepatocellular carcinoma and Cholangiocarcinoma**

15:35

Is it time for a new consensus on criteria for listing patients with HCC?
Pierre-Alan Clavien, Zurich, Switzerland

mTORi as standard immunosuppression in patients transplanted for HCC: What do the data show?
Edward Geissler, Regensburg, Germany

Liver transplantation for cholangiocarcinoma: selection, pre-transplant treatment, outcome
Julie Heimbach, Rochester, United States

**Discussion**

16:35

**Closing remarks**

16:45

Patrizia Burra, Padua, Italy

Others

14:30 - 16:30

Room 1.15

**Echocardiography (TEE) course: Transesophageal Echocardiography for Liver Transplantation**

**Chairs:**
Dmitri Bezinover, Hershey, United States
Jeron Zerillo, New York, United States

14:40

Transesophageal Echocardiography for Liver Transplantation
Cindy Wang, New York, United States
Thomas Verbeek, Hershey, United States

Others

17:00 - 18:20

Auditorium 1

**Opening Ceremony**

17:00

Welcome

17:10

ILTS Update

17:20

Presidential Address - Keynote Speech

17:45

President Elect Speech

17:55

Awards and Recognitions

Others

18:00 - 20:00

Exhibition Area

**Opening Reception / Exhibition Opening**
Scientific Programme

Poster Sessions
18:15 - 19:00

Poster Round I, Session 1: Acute Liver Failure

P-011 Pre-transplant de-arrangement of prothrombin time does not predict intra-operative blood product requirement during LDLT for ALF and ACLF
Nikunj Gupta, Gurgaon, India

P-012 The role and the timing of liver transplantation in drug induced acute liver failure

P-013 The immunosuppression strategy after liver transplant for acute liver failure
Deng Feiwen, Foshan, China

Poster Sessions
18:15 - 19:00

Poster Round I, Session 1: Alcoholic Liver Diseases / NASH / NAFLD

P-014 Alcoholic cirrhosis and psychic symptoms of patients listed for a liver transplantation: correlation and outcomes
Giovanna Mazzarone, Naples, Italy

P-015 Interesting biodata of cryptogenic cirrhosis - a single centre experience

Poster Sessions
18:15 - 19:00

Poster Round I, Session 1: Anesthesia / Critical Care Medicine

P-016 The impact of rotational thromboelastometry on resource utilization following liver transplantation
Mauro Enrique Tun-Abraham, London, Canada

P-017 Impact of renal dysfunction in immediate preoperative period on outcomes after liver transplantation: a comparative analysis

P-018 Red blood cell storage lesion does not impact post-transplant mortality after living donor liver transplantation
Kangha Jung, Seoul, Korea, Republic of

P-019 Antibiotic prophylaxis for gastrointestinal endoscopy-associated sepsis in cirrhotic patients waiting for liver transplantation
YiChia Chan, Kaohsiung, Taiwan, Republic of China

P-020 Incidence and impact of hyperfibrinolysis during liver transplantation in a multicenter study
Annabel Blasi, Barcelona, Spain

P-021 The predictive value of fibrinolytic activity phenotypes during liver transplantation
Evgeniia Kraisvetnaia, Saint Petersburg, Russian Federation

P-022 Postoperative coagulation profile in 50 living liver donors (thromboelastogram vs conventional tests): implications on epidural analgesia
G V Premkumar, Secunderabad, India
Scientific Programme

P-023  Assessment of the congruence between the TEG®5000 and the TEG®6S in liver transplant patients: a validation study
Jacqueline Robson, Sydney, Australia

P-024  Coronary artery calcium score as a screening test for cardiac evaluation in liver transplant recipients
Akila Rajakumar, Chennai, India

P-025  Major perioperative thrombotic events in liver transplant recipients
Christine Nguyen-Buckley, Los Angeles, United States

P-026  Universal use of prestorage leukoreduction did not decrease death risk after living donor liver transplantation
Suyong Jeon, Seoul, Korea, Republic of

P-027  Insulin therapy for postreperfusion hyperglycemia during liver transplantation: a retrospective cohort study
Seong Mi Yang, Seoul, Korea, Republic of

P-028  Osmotic demyelination syndrome following hyponatremia-oriented management in liver transplantation: in a single center twenty year experience
Gaab Soo Kim, Seoul, Korea, Republic of

P-029  PICCO monitoring during liver transplantation for pediatric patients
Zeynep Ersoy, Ankara, Turkey

P-030  Prediction of massive transfusion requirements during liver transplantation and its potential to reduce survival outcome

P-031  The role of prognostic scales in a real-life cohort of most severely ill cirrhotic patients - a single-center experience

Poster Sessions
18:15 - 19:00
Poster Area

Poster Round I, Session 1: Basic Science / Translational Research

P-033  The knockout of aldose reductase accelerates liver regeneration through AMPK/SIRT1/PGC-1α network
Chang Xian Li, Nanjing, China

P-034  IL-22 antibody attenuates acute graft-versus-host disease via increasing Foxp3+ T cells through modulating the function of CD11b+ cells

P-035  CCAAT-enhancer-binding protein homologous protein (CHOP) promotes liver ischemia and reperfusion injury by inhibiting Beclin-1-mediated autophagy in hepatocytes
Haoming Zhou, Los Angeles, United States

P-036  Engineering the liver: the use of decellularized human liver material and human liver-derived organoids for tissue engineering purposes
Jorke Willems, Rotterdam, Netherlands

P-037  Hyperplasia suppressor gene reduces vascular fibrosis after abdominal aorta transplantation in rat
### Scientific Programme

<table>
<thead>
<tr>
<th>P-038</th>
<th>Glutathione peroxidase 3 (GPx3) suppressed tumor growth and ameliorated hepatic IR injury via modulating autophagy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jie Zhou, Hong Kong, China</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-039</th>
<th>The plasma membrane-bound G protein-coupled bile acid receptor (TGR5) protected liver ischemia and reperfusion injury by regulating macrophage migration and polarization via AMPK/mTOR signaling</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haoming Zhou, Los Angeles, United States</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-040</th>
<th>5’AS KLHDC7B gene enhances liver regeneration via IL-6/STAT3 signaling pathway</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>P-041</th>
<th>IL23R is a pathogenic gene in type 1 regulatory T-cells during mouse liver transplant models</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>P-042</th>
<th>PARP-1 promotes tumor recurrence after warm ischemic donor liver transplantation through modulation on hepatic neutrophil phenotype</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xiao-Lei Shi, Nanjing, China</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-043</th>
<th>Tip60 suppresses cholangiocarcinoma proliferation and metastasis through PI3K-AKT-dependent manner</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>P-044</th>
<th>Sorafenib exhibit antifibrotic effects through STAT6 inhibition</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>P-045</th>
<th>Epithelial-mesenchymal transition regulated by Wnt/β-catenin signaling promotes tissue formation in hepatic differentiation from mouse ESCs</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>P-046</th>
<th>Experimental study of human gingival tissue-derived mesenchymal stem cells in management of chronic Graft-Versus-Host Disease (GVHD)</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>P-047</th>
<th>Exosome derived galectin 9 may be a novel predictor for rejection and prognosis after liver transplantation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Junjun Jia, Hangzhou, China</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-048</th>
<th>Experimental evaluation of liver regeneration patterns in small-for-size livers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ji-Hua Shi, Zhengzhou, China</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-049</th>
<th>Biliary reconstruction with PTFE graft in liver transplantation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ebru H. Ayvazoglu Soy, Ankara, Turkey</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-050</th>
<th>Ectopic lymphoid-like structures associates with progression and outcomes of liver cancer following liver transplantation</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>P-051</th>
<th>Activation of programmed death-1-homolog attenuate mouse liver regeneration after partial hepatectomy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cheukfai Li, Guangzhou, China</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-052</th>
<th>Different miRNA expression in transplanted livers of HCV mono-infected and HCV/HIV co-infected recipients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Umberto Baccarani, Udine, Italy</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-053</th>
<th>Proteasome activation during cold ischemia in fatty liver grafts preserved with IGL-1 or HTK Solutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arnau Panisello-Rosello, Barcelona, Spain</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-054</th>
<th>Aldehyde dehydrogenase-2 role and cyto-protective autophagy: underlaying mechanisms involved in fatty liver cold ischemia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arnau Panisello-Rosello, Barcelona, Spain</td>
<td></td>
</tr>
</tbody>
</table>
Adipose tissue derived mesenchymal stem cells in cirrhotics and healthy individuals: are they the same?
Kumara Swamy, New Delhi, India

A new fluorescence imaging technique for visualizing hepatobiliary structures using sodium fluorescein: result of a preclinical study in a rat model
Samyoul Yoon, Anyang, Korea, Republic of

The impact of the hypothalamus-pituitary-adrenal axis in brain-dead donors in steatotic liver transplantation
Elsa Negrete-Sánchez, Barcelona, Spain

Cost effectiveness of immunosuppression withdrawal after liver transplantation
Tommaso Maria Manzia, Rome, Italy

Everolimus after liver transplantation in the real life single-center cohort

Rapamycin induces a tolerogenic phenotype in dendritic cells in vitro
Geraldine Dahlqvist, Brussels, Belgium

Galectin-1 induced donor derived dendritic cells in combination with apoptotic lymphocytes promote immune tolerance of liver transplantation in rat
Lin Zhou, hangzhou, China

Liver transplant tolerance induced by severe or consistent infection revealed the association with T cell exhaustion

Reduction in circulating CD19+CD24+CD27+ regulatory B cell frequency predicts acute rejection in liver transplant patients
Haoming Zhou, Los Angeles, United States

Early administration of evrolimus did not compromise liver regeneration after living donor liver transplantation

The efficacy of Sofosbuvir/Ledipasvir or sofosbuvir/daclatasvir based therapies (with/without ribavirin) for recurrent hepatitis C (genotype 1,2) in liver transplantation recipients

Intramuscular hepatitis B immune globulin use in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Single center experience
Alba Cachero, Barcelona, Spain

Single center experience in HCC recurrence with DAA treatment in liver transplant recipients
Paria Mahboub, Worcester, United States
Scientific Programme

P-068  Genome analysis of hepatitis E virus isolates from twenty-one patients reveals a unique Singapore cluster  
Guan Huei Lee, Singapore, Singapore

P-069  Telbivudine improves posttransplant renal function with side effects

Poster Sessions  
18:15 - 19:00  
Poster Area

Poster Round I, Session 1: Donation after Cardiac Death

P-070  Short-term low dose methylprednisolone improves hyperbilirubinemia on EAD after DCD liver transplantation: a single center experience  
Joseph Attard, Birmingham, United Kingdom

P-071  Technical determinants of cholangiopathy in liver transplantation  
John LaMattina, Baltimore, United States

Poster Sessions  
18:15 - 19:00  
Poster Area

Poster Round I, Session 1: Machine Perfusion

P-072  The effect of end-ischaemic normothermic machine perfusion versus static cold storage on donor hepatic artery endothelial integrity: a preliminary study  
Joseph Attard, Birmingham, United Kingdom

P-073  Viability outcomes for donor livers discarded due to steatosis following extra-corporeal machine perfusion of the liver  
Yuri Boteon, Birmingham, United Kingdom

P-074  Pilot, open, monocentric, randomized, prospective trial for the evaluation of normothermic machine perfusion for organ preservation in liver transplantation using brain death donors ≥70 years  
Hashem Akbar, Baltimore, United States

P-075  Molecular adsorbent recirculating system support followed by liver transplantation for multiorgan failure from exertional heatstroke  
Hashem Akbar, Baltimore, United States

Poster Sessions  
18:15 - 19:00  
Poster Area

Poster Round I, Session 1: Donor Selection Criteria/patient selection/organ allocation

P-076  Reasons for donor rejection prior to living donor liver transplantation  
Sujeet Saha, Gurgaon, India

P-077  Donor liver apoptosis is associated with early allograft dysfunction and short-time graft survival after liver transplantation  
Zebin Zhu, Guangzhou, China

P-078  Frailty and reduced gait speed are associated to decreased survival in cirrhotic patients
Scientific Programme

P-079  Long-term outcomes of nationally versus regionally allocated liver allografts from three centers in three different UNOS regions

P-080  Expedited evaluation for liver transplantation: a critical look at processes and outcomes

P-081  Preoperative assessment of muscle mass using computerized tomography scans to predict outcomes following orthotopic liver transplantation
Thomas Resch, Innsbruck, Austria

P-082  Liver transplant recipients with end-stage renal disease largely benefit from kidney transplantation
Weiqiang Ju, Guangzhou, China

P-085  Liver transplant organ allocation: preliminary results using the ISO score system

P-086  Marijuana in liver transplant recipients
Pablo Serrano, Chapel Hill, United States

P-087  Time trends in liver transplantation for primary biliary cholangitis in Europe over the past three decades
Herold Metselaar, Rotterdam, Netherlands

P-088  Outcomes of organ transplantation from donors with cancer history
Shanzhou Huang, Guangzhou, China

P-089  Outcomes of liver transplantation with clonorchis-infected grafts: 5 cases and review of literature
Miu Yee Chan, Hong Kong, Hong Kong

P-090  Achieving acceptable one-year survival in well-selected septuagenarian liver transplant recipients

P-091  Evaluation of model for end-stage liver disease (MELD) score in selecting candidates for liver transplantation for acute-on-chronic liver failure
Guan Huei Lee, Singapore, Singapore

P-092  Organ utilisation in singapore - a 10-year analysis on utilisation trends in a organ scarce country

P-093  Incidental mixed hepatocellular and cholangiocarcinoma in patients who underwent liver transplantation - can we avoid a surprise?
Ming Yuan Tan, Singapore, Singapore

Poster Sessions
18:15 - 19:00

Poster Round I, Session 1: Living Donor

P-094  Retrograde extrabiliary cholangioplasty for advanced bile leaks after living donor liver transplantation
Yi-Ting Yeh, Taipei, Taiwan, Republic of China

P-095  Safety and risk factors of pure laparoscopic living donor right hepatectomy: comparison to open technique in propensity matched analysis
Gyu-Seong Choi, Seoul, Korea, Republic of
Scientific Programme

P-096 The learning curve in 100 consecutive live liver donors undergoing pure laparoscopic right hepatectomy

P-097 Anatomical variations of the right hepatic duct
  Samuel Obiekwe, Bordeaux, France

P-098 Donor outcomes in 1755 consecutive living donor liver transplants at a high volume center
  Amit Rastogi, Gurugram, India

P-099 Three-dimensional printing with biotexture modeling assisted donor left hepatectomy

P-100 Sarcopenia in cirrhosis before living donor liver transplantation
  Sencan Acar, Istanbul, Turkey

P-101 Barring stage 5 CKD in living donor scenario sequential and simultaneous CLKT in CLD with CKD have comparable outcomes - retrospective analysis of 2182 cases
  Naganathan Selvakumar, New Delhi, India

P-102 Reduced left lateral sector grafts for infants weighing less than 10 kilograms
  Zaza Iakobadze, Izmir, Turkey

P-103 Antegrade arterial and portal flushing versus portal flushing only for right lobe live donor liver transplantation - a randomized control trial

P-104 Donor wound satisfaction after living donor liver transplantation in the era of pure laparoscopic donor hepatectomy
  Jeong-Moo Lee, Seoul, Korea, Republic of

P-105 Demarcating the exact midplane of the liver using indocyanine green near-infrared fluorescence camera during laparoscopic donor hepatectomy

P-106 Comparison of liver graft regeneration between ABO-compatible and ABO-incompatible living donor liver transplantation: a propensity score matching analysis
  Hyo Min Yun, Gyeongsangnamdo, Korea, Republic of

P-108 The result of weight reduction program and the risk factors for failed weight reduction in patient with fatty liver during living donor liver transplantation workup

P-109 Early and late graft loss after right lobe living donor liver transplantation - a 20-year single centre experience
  W.C. Dai, Pokfulam, Hong Kong

P-110 A simplified technique of biliary anastomosis in right lobe living donor liver transplants: analysis of early bile leak

P-111 Clinical outcomes of totally laparoscopic living donor right hepatectomy
  Young Seok Han, Daegu, Korea, Republic of

P-112 Hybrid 3D laparoscopic donor right hepatectomy (HLDRH) is safe and feasible without the biliary complications of pure laparoscopic donor right hepatectomy (PLDRH)
  Thiagarajan Srinivasan, Gurgaon, India

P-113 Towards safer donor hepatectomies - a single centre learning curve analysis in living donor liver transplantation (LDLT)

P-114 Excellent outcomes after portal flow modulation in living donor liver transplantation
  Tiffany CL Wong, Hong Kong, Hong Kong
Scientific Programme

P-115  Better donor outcome following left lobe hepatectomy in adult-to-adult living donor liver transplant  
Kelvin K. Ng, Hong Kong, Hong Kong

P-116  Ex-vivo reconstruction of right lobe liver graft with a dacron caval interposition graft for 
Budd-Chiari syndrome without veno-veno bypass  
Swaminathan Sambandam, Coimbatore, India

P-117  Lessons learned from a single center experience of living donor liver transplant in the West  
James Hendele, Chicago, United States

P-118  A preoperative planning system of liver graft volumetry for living donor liver transplantation using Dr. Liver  
Hee Chul Yu, Jeonju-si, Korea, Republic of

Poster Sessions
18:15 - 19:00  
Poster Area

Poster Round I, Session 1: Pediatrics

P-119  Tacrolimus intracellular assay in peripheral blood mononuclear cells in paediatric liver transplant recipients: potential clinical implications  

P-120  Endoscopic treatment of biliary complications after pediatric liver transplantation in a high volume transplant center in Turkey  
Muhsin Murat Muhip Harputluoglu, Malatya, Turkey

P-121  Experience of post-transplant lymphoproliferative disorder (PTLD) after pediatric liver transplant: incidence, outcomes and association with food allergy  
Zeren Baris, Ankara, Turkey

P-122  Early portal vein thrombosis after pediatric liver transplantation: keys for successful management  
Franck Nounamo, Bergamo, Italy

P-123  Pediatric living donor liver transplantation with large-for-size left lateral segment grafts  
Nicolas Goldaracena, Toronto, Canada

P-124  Liver transplantation in progressive familial intrahepatic cholestasis: outcome analysis from a single centre  

P-125  Efficacy and safety of B-cell depletion in pediatric liver transplant recipients with EBV DNAemia and no posttransplant lymphoproliferative disease  

P-127  Incidence, clinical features and prognosis of food allergy in children who underwent liver transplantation  
Zeren Baris, Ankara, Turkey

P-128  Inbalance of Treg/Th17 in pediatric patients in different immunity post liver transplantation

Poster Sessions
18:15 - 19:00  
Poster Area

Poster Round I, Session 1: Outcomes / Complications
### Scientific Programme

<table>
<thead>
<tr>
<th>P-130</th>
<th>Early and late hepatic artery thrombosis after liver transplantation: a single-centre experience</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Yogesh Puri, London, United Kingdom</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-132</th>
<th>Long term follow-up of hereditary haemorrhagic telangiectasia patients who underwent liver transplantation for severe liver involvement</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Olivier Boillot, Lyon, France</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-133</th>
<th>Repeated episodes of acute kidney injury (AKI) on the transplant waiting list: impact on post-liver transplantation renal and patient outcomes</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>P-134</th>
<th>Selection and outcomes of living donor liver grafts for recipients weighing 6 kg or less: a single center experience</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Anisha Tiwari, Gurgaon, India</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-135</th>
<th>Compared with Rifampicin, the use of Rifabutin in adult living donor liver transplant recipients with tuberculosis does not decrease the incidence of graft rejection</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Chih-Che Lin, Kaohsing, Taiwan, Republic of China</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-136</th>
<th>Spokes on hub model with old horses for new courses! validation of a durable template for setting up safe deceased-donor transplant units in developing countries</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Ashwin Rammohan, Chennai, India</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-137</th>
<th>Characterization of the intestinal microbiome in diabetes after liver transplantation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mamatha Bhat, Toronto, Canada</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-138</th>
<th>Comparison of incidence and outcomes in early allograft dysfunction among LD, DCD and DBD grafts</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sreelakshmi Kotha, Toronto, Canada</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-139</th>
<th>Use of full-left-and-full-right split liver grafts: a systematic review and meta-analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Anne-Baue van Dijk, Rotterdam, Netherlands</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-140</th>
<th>Molecular profiles differentiate hepatorenal syndrome from other causes of renal dysfunction in cirrhotic patient waiting for liver transplantation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Elissa Bardhi, charlottesville, United States</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-141</th>
<th>Excellent outcomes after liver transplantation in patients with chronic portal vein thrombosis: role of extensive thrombectomy and back-up multivisceral transplantation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Chandrashekhar Kubal, Indianapolis, United States</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-142</th>
<th>Living donor liver transplantation for moderate to very severe hepatopulmonary syndrome: an experience of 24 patients</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sanjiv Saigal, Gurgaon, India</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-143</th>
<th>Liver transplantation in patients with acute-on-chronic-liver-failure and long term outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Antonella Putignano, Brussels, Belgium</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-144</th>
<th>Piggyback or cava replacement - which technique is protective against acute kidney injury after transplantation? A single center analysis of 378 cases</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Jeannette Widmer, London, United Kingdom</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-145</th>
<th>Role of hypercoagulability and DIC in thrombotic and hemorrhagic complications in visceral transplantation: a TEG-guided analysis and management algorithm</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Yehuda Raveh, Miami, United States</td>
</tr>
</tbody>
</table>
P-146 Long-term follow-up of patients with primary sclerosing cholangitis undergoing liver transplantation with duct-to-duct biliary
Laia Coromina Hernandez, Cleveland, United States

P-147 Is telbivudine-induced polyneuropathy/myopathy reversible in liver transplant recipients?

P-148 Cellular crosstalk during ischemia reperfusion injury in liver transplantation as indicator of short-term outcomes: identifying pathways of injury and future targets for interventions
Brandon Cho, Charlottesville, United States

P-149 Derivation and prospective external validation of prediction models for acute kidney injury in adult liver transplant recipients

P-150 Toll-like receptor 9 -1486C/T genetic polymorphism is associated with hepatocarcinoma recurrence after liver transplantation
Valentín Cuervas-Mons Martínez, Majadahonda, Spain

P-151 Early clostridium difficile infection and risk factors analysis in liver transplant adult recipients: a single center experience
Shih Min Yin, Kaohsiung, Taiwan, Republic of China

P-153 Role of procalcitonin in predicting new onset sepsis and in guiding immunosuppressant therapy in early post liver transplantation period
Rather Shiraz, Trivandrum, India

P-154 ABOi adult living donor liver transplantation carried higher biliary complications even under microscopic approach

P-155 Decreased expression of pro-carcinogenic genes following tacrolimus to sirolimus conversion in liver transplant recipients
Mamatha Bhat, Toronto, Canada

P-156 Enhanced recovery program: an effective tool for post-operative care of liver transplanted patients
Antonio Romano, Stockholm, Sweden

P-157 Surgical complications requiring an early relaparotomy in HIV infected liver transplanted patients: any specific susceptibility?

P-158 New onset hepatic steatosis after liver transplant is often seen but does not impact post-transplant survival: a single center experience
David Victor, Houston, United States

P-159 Comprehensive complication index measure at moment of post-liver transplant discharge well predicts long-term survival
Fabio Melandro, Rome, Italy

P-160 Factors associated with the development of chronic kidney disease after liver transplantation
Marit Kalisvaart, Birmingham, United Kingdom

P-161 Is retreat score applicable to living donor liver transplant patients with HCC
Muhammad Osama Tariq Butt, Islamabad, Pakistan

P-162 Dunbar syndrome in liver transplantation: results of a single center matched-pair analysis and a European survey study
Zoltan Czigany, Aachen, Germany
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Author(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-163</td>
<td>Platelet counts as predictors of short- and long-term outcomes in liver transplantation: Cassandras or just rats on a sinking ship?</td>
<td>Zoltan Czigany, Aachen, Germany</td>
</tr>
<tr>
<td>P-164</td>
<td>When less is more: small for size versus dual grafts in living donor liver transplantation</td>
<td>Abu Bakar Hafeez Bhatti, Islamabad, Pakistan</td>
</tr>
<tr>
<td>P-165</td>
<td>The success of Kaffes stent insertions for post liver transplant anastomotic strictures</td>
<td>Ben Warner, London, United Kingdom</td>
</tr>
<tr>
<td>P-166</td>
<td>Post-transplant muscle mass measured by urinary creatinine excretion rate predicts long-term outcomes after liver transplantation</td>
<td></td>
</tr>
<tr>
<td>P-167</td>
<td>Saphenous vein conduits for hepatic arterial reconstruction in living donor liver transplantation</td>
<td>Abu Bakar Hafeez Bhatti, Islamabad, Pakistan</td>
</tr>
<tr>
<td>P-168</td>
<td>Single center experience of 5,000 cases of liver transplantation at Asan Medical Center</td>
<td>Jung Ja Hong, Seoul, Korea, Republic of</td>
</tr>
<tr>
<td>P-169</td>
<td>High recipient MELD score has a negative influence on the outcome of right-extended split liver transplantation</td>
<td></td>
</tr>
<tr>
<td>P-170</td>
<td>The influence of donor metabolic factors on long-term liver graft survival</td>
<td>Wojciech Polak, Rotterdam, Netherlands</td>
</tr>
<tr>
<td>P-171</td>
<td>Livers from donation after circulatory death donors can be safely used for retransplantation</td>
<td>Marjolein van Reeven, Rotterdam, Netherlands</td>
</tr>
<tr>
<td>P-172</td>
<td>Multi-omics approach assess effect of ischemia reperfusion injury on early graft injury post-liver transplantation</td>
<td>Angela Fernandez, Charlottesville, United States</td>
</tr>
<tr>
<td>P-173</td>
<td>The mechanism of circRNA_0046367/miR-33/ABCA1 regulatory system in lipid homeostasis of liver transplant</td>
<td>Xiao Xu, Hangzhou, China</td>
</tr>
<tr>
<td>P-175</td>
<td>Three months outcome analysis after delayed abdominal fascial closure in adult liver transplantation</td>
<td>Ivan Vella, Rome, Italy</td>
</tr>
<tr>
<td>P-177</td>
<td>Autoimmune hepatitis recurrence after liver transplantation in a single center study: associated risk factors</td>
<td>Luís Teles, Santa Maria da Feira, Portugal</td>
</tr>
<tr>
<td>P-178</td>
<td>Incidence, significance and outcome of ischemia-reperfusion injury in 1113 living donor liver transplants</td>
<td>Narendra Singh Choudhary, Gurgaon, India</td>
</tr>
<tr>
<td>P-179</td>
<td>Extracellular microvesicles from liver perfusate: microRNAs, cellular cross-talk, and early-post liver transplant outcomes</td>
<td>Olivia Ingram, charlottesville, United States</td>
</tr>
<tr>
<td>P-180</td>
<td>Reno-portal bypass for non tumorous portal vein thrombosis in adult liver transplantation</td>
<td>Domenico Pinelli, bergamo, Italy</td>
</tr>
<tr>
<td>P-181</td>
<td>Analysis of the predictive ability for graft loss and mortality of two criteria for early allograft dysfunction after liver transplantation</td>
<td>Yiliam Fundora-Suarez, Granada, Spain</td>
</tr>
</tbody>
</table>
The first fifteen days of calcineurin inhibitors exposure do not predict post-transplant malignant outcomes
Tommaso Di Maira, Valencia, Spain

Frequency of thyroid dysfunction in patients with diabetes mellitus before and after liver transplantation
Luciana Teixeira Lot, Campinas, Brazil

Excellent outcomes for transplantation for HCC beyond Milan criteria: a single center experience
David Victor, Houston, United States

Association between preoperative source of infection and clinical outcome in deceased donor liver transplantation
Deok Gie Kim, Seoul, Korea, Republic of

Impact of the material on the patency of reconstructed middle hepatic vein in living donor liver transplantation using the right liver
Soo Ho Lee, Uijeongb-si, Korea, Republic of

Validity of Doppler ultrasound as long term follow up in liver transplant recipients
Pablo Serrano, Chapel Hill, United States

Donor specific anti-HLA antibodies are not associated with non-anastomotic biliary strictures but both are independent risk factors for graft loss after liver transplantation
Bart van Hoek, Leiden, Netherlands

Domino liver transplantation and acquired familial amyloid polyneuropathy

Routine flow measurements and aggressive inflow modulation prevents flow-related complications in both deceased and living donor liver transplantation recipients
Yee Lee Cheah, Burlington, United States

Preformed donor-specific antibodies do not affect the one-year allograft survival in living donor liver transplantation
Hyeyoung Kim, Seoul, Korea, Republic of

Midodrine conveys increased risk for waitlist mortality in liver transplant patients
Jennifer Kalil, Chicago, United States

Outcomes retrospective comparative study about interferon-based versus direct-acting antiviral (DAA)-based preemptive treatment of HCV after living donor liver transplantation
Jae Hyun Kwon, Seoul, Korea, Republic of

Impact of early allograft dysfunction (EAD) and its components on the development of acute kidney injury (AKI) following liver transplantation alone (LTA)
Burcin Eksir, Indianapolis, United States

Transplant hepatectomy with portacaval shunt and molecular adsorbent recirculating system (MARS) therapy for periparative catastrophe
Arielle Cimeno, Baltimore, United States

Deregulation of predisposed Ankyrin-G increases the risk of HCC and HBV recurrence after liver transplantation in HCC recipients
Kevin Tak-Pan Ng, Hong Kong, China
Scientific Programme

P-198  Inadvertent PAC cannulation of the right subclavian artery in a living related liver transplant recipient: rescue, remedy and sequelae
Sook Muay tay, singapore, Singapore

P-199  Early hepaticojejunostomy for post LDLT biliary strictures is safe and provides durable outcomes
Jasper Sandeep Rajasekar, Chennai, India

P-200  Fecal microbiome as a potential biomarker for liver transplantation evolution: an European single center experience
Cristina Dopazo, BARCELONA, Spain

P-201  Liver transplantation in patients with spontaneous spleno-renal shunt

P-202  A new approach to overcoming biliary complications after laparoscopic living donor liver transplantation
Ji Soo Lee, Seoul, Korea, Republic of

P-203  Living donor liver transplantation provided an excellent outcome for acute on chronic failure patients
Humaira alam, kaohsiung, Taiwan, Republic of China

Poster Sessions
18:15 - 19:00
Poster Area

Poster Round I, Session 1: Radiology and Pathology

P-204  The role of microsatellite instability associated proteins, polyomavirus and P53 in posttransplant lymphoproliferative disorders (PTLD)

P-205  Late liver allograft dysfunction: histopathological spectrum with analysis of rejection histology

P-206  Significant improvement of MR cholangiopancreatography image quality with oral administration of effervescent agent
Heon-Ju Kwon, Seoul, Korea, Republic of

P-207  Interventional treatment of a biliary stricture after adult right-lobe living-donor liver transplantation with duct-to-duct anastomosis
Dong Goo Kim, Seoul, Korea, Republic of

P-208  Study of anatomical variations of hepatic vasculature using multidetector computer tomography (MDCT) angiography in 500 patients
Abeer Syed Anwar, New Delhi, India

P-211  Hepatic artery Doppler flow changes during cholangitis in liver transplantation patients
Nihal Uslu, Ankara, Turkey

Poster Sessions
18:15 - 19:00
Poster Area

Poster Round I, Session 1: Malignancies
Scientific Programme

P-212  Transplanting resectable hepatocellular carcinoma - an once for all treatment modality
Ka Wing Ma, Hong Kong, Hong Kong

P-213  Comparison of low-AFP-secreting versus high-AFP-secreting hepatocellular carcinomas in liver transplantation
Behnam Saberi, Baltimore, United States

P-214  Postoperative morbidity as predictor of early recurrence and poor survival following major hepatectomy for advanced perihilar cholangiocarcinoma

P-215  Development of cisplatin-loaded poly (ethylene glycol) and gelatin-based hydrogels for transarterial chemoembolization in a mouse model of orthotopic liver cancer
Xin Xiang Yang, Hong Kong, Hong Kong

P-216  The surgical outcome of salvage living donor liver transplantation for hepatocellular carcinoma is dependent on the learning curve: a comparative study with propensity score analysis

P-217  De novo malignancies in 1639 consecutive living donor liver transplant recipients
Anisha Tiwari, Gurgaon, India

P-218  A multicenter study to assess the incidence of hepatocellular carcinoma recurrence after liver transplantation in patients treated with direct-acting antivirals for chronic hepatitis C
Andre Gorgen, Toronto, Canada

P-219  Alpha-fetoprotein dynamics in the waiting list as a biomarker of hepatocellular carcinoma recurrence and mortality after liver transplant
Wei Zhang, Toronto, Canada

P-220  Therapy of patient with recurrent HCC after liver transplantation with T-cells transiently expressing HBV-specific TCR

P-221  Clinical analysis of patients with portal vein tumor thrombi after living donor liver transplantation
Dong Goo Kim, Seoul, Korea, Republic of

P-222  Management and outcome of HCC recurrence after living donor liver transplantation according to expanded criteria regardless of size and number
Prashant Bhangui, Medanta, India

P-223  ANXA2 exacerbates cholangiocarcinoma malignancy via preventing β-catenin from degradation

P-225  99mTc technetium-mebrofenin hepatobiliary scintigraphy predicts portal hypertension in Child-Pugh A cirrhosis
Bart Bracke, Edegem, Belgium

P-226  Downstaging in cirrhotic and non-cirrhotic patients with multinodular hepatocellular carcinoma exceeding Milan criteria
Annelotte Broekhoven, Leiden, Netherlands

P-227  Excellent outcomes for liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy comparable to locally advanced hilar cholangiocarcinoma: a single center experience

P-228  Impact of alpha-fetoprotein progression slope on cancer-specific mortality after liver transplantation for hepatocellular carcinoma in cirrhotic patients within Milan criteria
Franck Nounamo, Bergamo, Italy
P-229  Single nucleotide polymorphisms of CXCL9 (rs10336) and CXCL10 (rs3921) are not associated with hepatocellular carcinoma in alcoholic liver disease
Ana Ostojic, Zagreb, Croatia

P-230  Liver transplantation for hepatocellular carcinoma: the Milan criteria and beyond

P-232  Classical type and high degree of tumor necrosis are associated with early recurrence after liver transplantation for combined hepatocellular carcinoma-cholangiocarcinoma
Woong Ki Park, Seoul, Korea, Republic of

P-233  CXCL2 inhibits hepatocellular carcinoma progression in vitro
Jun Ding, Hangzhou, China

P-234  Complete pathological necrosis of hepatocellular carcinoma is determinant of the best cancer specific survival after liver transplantation, what are the pre-transplant predictors?
Chih-Che Lin, Kaohsing, Taiwan, Republic of China

P-235  Neutrophil to lymphocyte ratio lead to poor prognosis of hepatocellular carcinoma after liver transplantation through regulation of systemic cancer- and immune- related factors
Chih-Che Lin, Kaohsing, Taiwan, Republic of China

P-236  Risk for infection and non-infection related malignancies following immunosuppression in a cohort of liver transplant recipients, Italy 1985 - 2014
Martina Taborelli, Aviano PN, Italy

P-237  Potassium channel KCa3.1 targets SKP2 and RELN to promote the progression of hepatocellular carcinoma
Song Penghong, Hangzhou, China

P-238  Synergistic anticancer effect of metformin in combination with immunosuppressant on hepatocellular carcinoma cell lines
Suk-Won Suh, Seoul, Korea, Republic of

P-239  Microwave laparoscopic ablation and salvage transplantation for patients with hepatocellular carcinoma

P-240  Liver transplant post neoadjuvant chemo-radiotherapy for hilar cholangiocarcinoma: a technical challenge but not a higher risk transplant
Barbara Fiore, Dublin, Ireland

P-241  Liver transplantation and cava replacement for myofibroblastic tumor involving the three suprahepatic veins in a pediatric patient: a case report and literature review

Poster Round I, Session 1: Late Breaking Abstracts

LB P-024  Improved survival in liver transplant patients receiving prolonged-release Tacrolimus in the European Liver Transplant Registry (ELTR): long-term follow-up, extension study
Vincent Karam, Villejuif, France

LB P-025  Changes in transfusion practice with introduction of rotational thromboelastometry (ROTEM) in deceased donor liver transplantation (DDLT)
Jana Hudcova, Burlington, United States

LB P-026  Can pediatric livers be safely used in adult recipients
### Scientific Programme

<table>
<thead>
<tr>
<th>LB P-027</th>
<th>ERO1α promotes hepatocellular carcinoma metastasis and angiogenesis through S1PR1/STAT3/VEGF-A pathway</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Jianhua Rao, Nanjing, China</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LB P-028</th>
<th>Impact of middle hepatic vein reconstruction on living donor liver transplantation using right hemiliver graft</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sung Yeon Hong, Suwon, Korea, Republic of</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LB P-029</th>
<th>miR-155-5p modulates malignant behaviors of hepatocellular carcinoma by directly targeting CTHRC1 and indirectly regulating GSK-3β-involved Wnt/β-catenin signaling</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>LB P-030</th>
<th>Prospective multicenter study about cardiovascular events after liver transplantation</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>LB P-031</th>
<th>Prediction model of graft utilization and patient outcome in liver transplantation from donors after circulatory death</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>LB P-032</th>
<th>Low weight DCD donor pediatric liver transplantation - a single center experience</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>LB P-033</th>
<th>Benefit of anti-hepatitis B immunoglobulin(HBIG) monotherapy compared to HBIG combined with entecavir in long term renal function</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Munseok Choi, Seoul, Korea, Republic of</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LB P-034</th>
<th>Orthotopic liver transplantation for mixed-cellularity hepatocarcinoma-intrahepatic cholangiocarcinoma: a single centre experience</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mihnea Ioan Ionescu, Birmingham, United Kingdom</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LB P-035</th>
<th>The effects of diastolic dysfunction (DD) defined by the electrocardiographic measures of ventricular repolarization (EMVR) on outcomes after deceased donor liver transplantation (ddLT)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Jana Hudcova, Burlington, United States</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LB P-036</th>
<th>Outcome of living donor liver transplantation in patients of hepatocellular carcinoma after adrenalectomy for solitary adrenal gland metastasis: can we achieve long term survival?</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Horng-Ren Yang, Taichung, Taiwan, Republic of China</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LB P-037</th>
<th>Survival analysis after liver transplant with cadaveric donor and liver kidney transplant in Argentina</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>LB P-038</th>
<th>Long-term analysis for biliary complications after duct-to-duct biliary reconstruction in living donor liver transplantation: risk factors and impact of external biliary stent</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sung Yeon Hong, Suwon, Korea, Republic of hold</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LB P-039</th>
<th>Donation after circulatory death type 2 liver transplantation in a large referral centre in the United Kingdom: a feasibility study</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mihnea Ioan Ionescu, Birmingham, United Kingdom</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LB P-040</th>
<th>Aetiology of delirium post liver transplant and the effect on inpatient length of stay</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Oliver Tavabie, London, United Kingdom</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LB P-041</th>
<th>Perioperative characteristics of liver transplantation for methylmalonic acidemia and management experience</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Yizhou Jiang, Beijing, China</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LB P-042</th>
<th>Effect of type of fluid during donor hepatectomy on post operative donor outcome. Our experience of 900 cases of living related liver transplants</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>LB P-043</th>
<th>Neurological complications after liver transplant: a frequent and disturbingly heterogeneous phenomenon</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Marcela Benitez, Buenos Aires, Argentina</td>
</tr>
</tbody>
</table>
Scientific Programme

LB P-044  The effect of donor-derived infections on liver transplantation recipients
Wei Song, Beijing, China

LB P-045  Liver transplant in acute on chronic liver failure - a single center experience
Shashwat Sarin, New Delhi, India

LB P-046  Comparison of different components of rotational thromboelastometry (ROTEM) in relation to consumption of Fresh Frozen Plasma (FFP) in deceased donor liver transplantation (DDLT)
Jana Hudcova, Burlington, United States

LB P-047  The potential utility of a hemadsobtion column (CytoSorb®) in patients with acute liver failure
Dana Tomescu, Bucharest, Romania

LB P-048  Orthotopic liver transplant and post-operative renal replacement therapy: a 5 year review
Siobhan McGuinness, Dublin, Ireland

LB P-049  Bile duct anatomy of caudate lobe in living donor evaluated by Gd-EOB-DTPA-enhanced 3D T1-weighted MR cholangiography
Heon-Ju Kwon, Seoul, Korea, Republic of

LB P-050  Aging aggravates hepatic ischemia reperfusion injury by impairing mitophagy with involvement of EIF2α-parkin pathway
Yang Li, Guangzhou, China

LB P-051  Higher risk of post-transplant graft failure in male recipients of female donor grafts may be not due to anastomotic size disparity
Chung Young Jae, Seoul, Korea, Republic of

LB P-052  Liver transplantation in Kazakhstan: single center experience of first 100 cases
Baimakhanov Zhassulan, Almaty, Kazakhstan

LB P-053  Treatment of anastomotic bilo-biliary stricture after adult liver transplantation: a retrospective study over 25 years in a single center
Olivier boillot, Lyon, France

LB P-054  Unusual cause of post-liver transplant insufficient portal inflows in patient with low portal stream: splenic venous steal

LB P-055  Portal venous velocity affects liver regeneration after right lobe living donor hepatectomy: prospective cohort study

LB P-056  Vancouver scar scale in evaluating scars after living donor hepatectomy

LB P-057  Case series of intraoperative continuous replacement renal therapy through the venovenous bypass circuit during orthotopic liver transplant, a novel approach
Christine Myo Bui, Los Angeles, United States

LB P-058  The combination of MMF and FK506 within single nanoparticle platform for the treatment of acute rejection after liver transplantation in rats
Haiyang Xie, Hangzhou, China

LB P-059  Does the old graft benefit from a young recipient - influence of donor recipient age discrepancy (DRAD) in liver transplantation
Yasuhito Iwao, London, United Kingdom
Scientific Programme

LB P-060 The percentage-change of graft-derived cell-free DNA in ornithine transcarbamylase deficiency patient after living-donor liver transplantation
Hai-Rui Wu, Beijing, China

LB P-061 The value of routine cholangiography on the diagnosis of biliary tract complications after liver transplantation

LB P-062 First bilateral lung and liver transplant due to cystic fibrosis in Latin America
Pablo Farinelli, Capital Federal, Argentina

LB P-063 Splenic artery transposition for the repair of a mycotic pseudoaneurysm of the hepatic artery after liver transplantation - a case report

Poster Sessions
18:15 - 19:00
Poster Area

Poster Session: Surgical Videos 1

eP-001 Total laparoscopic living donor right hepatectomy for modified extended right graft
Jai Young Cho, Seongnam, Korea, Republic of

eP-002 Totally laparoscopic right hepatectomy for adult living donor liver transplantation with unfavored anatomy
Young Jae Chung, Seoul, Korea, Republic of

Poster Sessions
19:00 - 20:00
Poster Area

Vanguard Moderated Poster Discussion

Chairs:
Didier Samuel, Villejuif, France
Claus Niemann, San Francisco, United States
Valeria Mas, Charlottesville, United States
Chao-Long Chen, Kaohsiung, Taiwan, Republic of China

P-001 Prognostic index consisting of platelet count, total-bilirubin, and prothrombin time on postoperative day-14 accurately predict recipient mortality in adult-to-adult living-donor liver transplantation: a single-center analysis
Jiro Kusakabe, Kyoto, Japan

P-002 Cabazitaxel, a novel chemotherapeutic alternative for drug-resistant hepatocellular carcinoma
Ronggao Chen, Hangzhou, China

P-003 Transplantation of a human iPSC-derived hepatocyte sheet protect a rat model of small-for-size liver transplantation

P-004 Treating vasoplegic syndrome in liver transplantation with hydroxocobalamin: a case series

P-005 Proposal of prognostic survival models before and after liver resection for hepatocellular carcinoma in potentially transplantable patients
Stefano Di Sandro, Milan, Italy
Scientific Programme

P-006  Total plasma exchange for management of early allograft dysfunction after adult living donor liver transplantation  
Jasper Sandeep Rajasekar, Chennai, India

P-007  Effect of coronary artery disease and pre transplant coronary intervention in LDLT recipients  
Vijay Vohra, Gurugaon, India

P-008  Multiple graft hepatic arteries in right lobe live donor liver transplantation: outcome with a policy of selective re-vascularization  
Sujeet Saha, Gurgaon, India

P-009  Split liver transplantation reduces mortality on waiting list with high rate of biliary complications but no different post transplant mortality: 111 consecutive cases

P-010  Is Body Mass Index as a predictor of hepatic steatosis in living liver donors?  
Birkan Bozkurt, Istanbul, Turkey
The 2018 Annual ILTS Meeting,
May 23-26, 2018,
Lisbon, Portugal

Scientific Programme

Thursday, 24 May 2018

Vanguard Sessions
06:30 - 07:30
Restaurant CCL

Vanguard Grand Round Case Presentations

Chairs:
Alan Contreras, Mexico, Mexico
Ashish Singhal, Mohali, India

- **Recurrent portal vein thrombosis after liver transplantation for Budd-Chiari syndrome despite aggressive anticoagulation treatment.**
  Miriam Cortes Cerisuelo, London, United Kingdom
  06:30

- **Splanchnic Venous Thrombosis**
  06:30

- **II. Cholangiopathy: Insight from Explant Liver Graft from a Child with Severe Post Operative Hypoxemia due to Hepatopulmonary Syndrome**
  Joseph Valamparampil, Chennai, India
  Roberto Hernandez-Alejandro, Rochester, United States
  06:50

- **III. Systolic Anterior Motion of Mitral Valve after Reperfusion in Liver Transplantation**
  Uzung Yoon, Philadelphia, United States
  Victor Xia, Los Angeles, United States
  07:10

Rising Star Symposium
08:00 - 10:00
Auditorium 1

Rising Star Plenary Session

Chairs:
Patrizia Burra, Padua, Italy
Nancy Kwan Man, Hong Kong, Hong Kong

- **Towards graft engineering using decellularized porcine liver scaffolds and recellularization with human liver organoids**
  Jorke Willemse, Rotterdam, Netherlands
  Monique M.A. Verstegen, Rotterdam, Netherlands
  08:00

- **Superior outcomes using normothermic regional perfusion in cDCD liver transplantation**
  Amelia Hessheimer, Barcelona, Spain
  Constantino Fondevila, Barcelona, Spain
  08:20

- **Pure laparoscopic right hepatectomy in living donors: 115 cases in an experienced adult living donor liver transplant center**
  Suk Kyun Hong, Seoul, Korea, Republic of
  Kyung-Suk Suh, Seoul, Korea, Republic of
  08:40

- **Gene silencing with si-RNA alleviates ischemia-reperfusion injury in the liver: potential utilization during normothermic machine preservation**
  Paulo Martins, Worcester, United States
  09:00
Scientific Programme

O-005  Δ42PD-1 expressed M2 macrophages promoted tumor recurrence after liver transplantation
Wai Ho Oscar Yeung, Hong Kong, China
Nancy Kwan Man, Hong Kong, Hong Kong

O-006  Retransplantation after living donor liver transplantation: The North American Experience
Hillary Braun, San Francisco, United States
Nancy Ascher, San Francisco, United States

Poster Sessions
10:00 - 10:45
Poster Area

Poster Session: Surgical Videos 2

eP-004  Budd Chiari syndrome with caval thrombosis: technical strategies for successful left lobe or right lobe living donor liver transplantation
Mettu Reddy, Chennai, India

eP-005  Laparoscopic donor heptectomy - the way forward: first case report from India GEM hospital and research centre, Coimbatore, India

eP-006  A simple back benching test to assess the implantability of inferior hepatic veins in right lobe grafts
Vachan Hukkeri, Delhi, India

Poster Sessions
10:00 - 10:45
Poster Area

Poster Round I, Session 2

For a complete list of posters please see Poster Round I, Session 1:
Click on Poster Round I, Session 1, taking place on Wednesday, 23.05.2018 18:15-19:00

Viewing Sessions of Poster Round I are:
Session 1 - Wednesday, 23.05.2018, 18:15-19:00
Session 2 - Thursday, 24.05.2018, 10:00-10:45
Session 3 - Thursday, 24.05.2018, 16:15-17:00

Concurrent (ELITA)
10:45 - 12:15
Auditorium 1

ELITA Symposium I NAS: The Achilles Heel of DCD Liver Transplantation

Chairs:
Gabriela A. Berlakovich, Vienna, Austria
Wojciech Polak, Rotterdam, Netherlands
Scientific Programme

Pathophysiology and best prophylaxis of non-anastomotic biliary strictures a. Minimizing graft ischemia  b. The role of fibrinolytic therapy
Humberto Bohorquez, New Orleans, United States
Robert Porte, Groningen, Netherlands

Regional perfusion vs. machine perfusion in controlled DCD: a. Regional perfusion b. Machine perfusion
Constantino Fondevila, Barcelona, Spain
Philipp Dutkowski, Zurich, Switzerland

Herold Metselaar, Rotterdam, Netherlands
Nigel Heaton, London, United Kingdom

Featured Symposium
10:45 - 12:15
Auditorium 2

Anesthesia/Critical Care - Risk assessment is a team business

Chairs:
John Roberts, San Francisco, United States
John Klinck, Cambridge, United Kingdom

Cardiovascular assessment of the liver transplant candidate
James Findlay, Rochester, United States

Are elderly donors a risky business?
Davide Ghinolfi, Pisa, Italy

Coagulation management for invasive procedures before LT
Fuat Saner, Essen, Germany

Frailty as an outcome predictor - better than MELD
Lorena Puchades, Valencia, Spain

Featured Symposium
10:45 - 12:15
Auditorium 6

AKI post liver transplantation - From bedside to bench

Chairs:
Elizabeth Pomfret, Denver, United States
Marina Berenguer, Valencia, Spain

Diagnosis of AKI & Assessment of Renal Function
Mitra Nadim, United States

Pre-operative prevention & treatment of AKI
Claire Francoz, Clichy, France

Perioperative & Intraoperative risk factors for AKI: recipient, donor and surgical
Rajiv Jalan, London, United Kingdom
Scientific Programme

**Acute kidney injury post-liver transplantation: A complex molecular and cellular organ cross-talk**
Gebhard Wagener, New York, United States

11:39

**Suppression of renal mitochondrial biogenesis, a novel mechanism of acute kidney injury after cholestatic liver fibrosis and liver transplantation**
Zhong Zhi, Charleston, United States

11:57

Featured Symposium
10:45 - 12:15
Auditorium 7

**Transplant Oncology - Recurrent Hepatocellular Carcinoma**

Chairs:
Pierre-Alan Clavien, Zurich, Switzerland
Kim Olthoff, Philadelphia, United States

- **Metroticket 2.0 Model for HCC recipient**
  Vincenzo Mazzaferro, Milan, Italy
  10:45

- **Transplant benefit score for organ allocation**
  John O'Grady, London, United Kingdom
  11:03

- **Treatment algorithm for recurrent HCC**
  Albert Chi Yan Chan, Hong Kong, Hong Kong
  11:21

- **Recurrent HCC following curative therapy: Is it modified by DAA?**
  Maria Reig, Barcelona, Spain
  11:39

- **Pushing the envelope for recurrence - the surgeon’s role**
  Taizo Hibi, Tokyo, Japan
  11:57

Featured Symposium
10:45 - 12:15
Auditorium 8

**Graft injury - mechanisms and therapies**

Chairs:
Nancy Kwan Man, Hong Kong, Hong Kong
Luc van der Laan, Rotterdam, Netherlands

- **System biology in liver transplantation - the future is now**
  Valeria Mas, Charlottesville, United States
  10:45

- **An integrated approach for predicting disease recurrence after liver transplantation**
  Kevin Tak-Pan Ng, Hong Kong, China
  11:03

- **Experimental Approaches to Target hepatic I/R Injury and clinical potentials**
  Yuan Zhai, Los Angeles, United States
  11:21
Scientific Programme

DCD cholangiopathy, is this truly ischemic injury? 11:39
Jeroen de Jonge, Rotterdam, Netherlands

Marginal liver graft injury - the view from pathologist 11:57
Jimin (Nancy) Liu, Oakville, Canada

Women in LT lunch gathering

MELD disadvantage in women 12:30
Monika Sarkar, San Francisco, United States

Gender mismatch between donor and recipient. When does it matter 12:50
Francois Durand, Paris, France

Women in academic Liver Transplantation Surgery 13:10
Susan Orloff, Portland, United States

State of the Art I

Chairs:
Nancy Kwan Man, Hong Kong, Hong Kong

PSC: from basic science to liver transplantation 14:00
Tom Hemming Karlsen, Oslo, Norway

Living Donor

Chairs:
Kwang-Woong Lee, Seoul, Korea, Republic of
Elizabeth Pomfret, Denver, United States

O-007 Myeloid-derived suppressor cells mobilization through CXCL10/TLR4 signaling promotes liver tumor growth after LDLT 14:45
Hui Liu, Hong Kong, Hong Kong

O-008 A predictive risk scoring system for the development of persistent massive ascites after living donor liver transplantation - to begin with the end in mind 14:55
Yi-Ju Wu, Kaohsiung, Taiwan, Republic of China

O-009 Early combination of everolimus and mycophenolic acid in the live donor liver transplant setting: efficacy and safety 15:05
Mohamed El-Saadany, Mansoura, Egypt
The 2018 Annual ILTS Meeting,
May 23-26, 2018,
Lisbon, Portugal

Scientific Programme

O-010  Outcomes of living donor liver transplantation for grade 3 acute-on chronic liver failure
Sanjay Kumar Yadav, Gurgaon, India

O-011  Live liver donors: is left still right?
Ashwin Rammohan, Chennai, India

O-012  The impact of total ischemia time on post-operative biliary stricture in living donor liver transplantation
Norio Kawamura, Sapporo, Japan

O-013  Surgical complications after right heptectomy for live liver donation. A single center experience after 587 cases
Andre Gorgen, Toronto, Canada

O-014  Hemi-porto-caval shunt as a measure to expand donor pool by allowing successful living donor liver transplantation with small-for size grafts
Sanjay Kumar Yadav, Gurgaon, India

O-015  The Toronto experience with 50 anonymous live liver donors
Nicolas Goldaracena, Toronto, Canada

Concurrent (LICAGE)
14:45 - 16:15
Auditorium 2

LICAGE Parallel Session I: The marginal LT candidate: who, what, when

Chairs:
Gianni Biancofiore, Pisa, Italy
Catherine Paugam-Burtz, Paris, France

A candidate with ACLF: Can we avoid futile transplantation?
Ram Subramanian, Atlanta, United States

A candidate with kidney failure: perioperative optimization
Pere Gines, Barcelona, Spain

A candidate with severe lung disease: what are the limits, what are the options?
Michael Krowka, Rochester, United States

A candidate with portal vein thrombosis: treat and transplant or deny?
Marco Senzolo, Padua, Italy

Others
14:45 - 16:15
Auditorium 3

Parallel Session for Pediatrics: The sick pediatric liver recipient

Chairs:
Michael Stormon, Sidney, Australia
Paolo Muiesan, Birmingham, United Kingdom
The 2018 Annual ILTS Meeting,
May 23-26, 2018,
Lisbon, Portugal

Scientific Programme

14:45
Liver disease in children with intestinal failure
Girish Gupte, Birmingham, United Kingdom

Surgical strategies for liver transplantation in pediatric acute liver failure
Paolo Muiesan, Birmingham, United Kingdom

Surgical innovation in pediatric liver transplant
Mureo Kasahara, Tokyo, Japan

Managing severe peri-transplant hypoxemia in children with hepatopulmonary syndrome
Anil Dhawan, London, United Kingdom

Vascular complication in pediatric recipient
Chao-Long Chen, Kaohsiung, Taiwan, Republic of China

Panel discussion

14:45 - 16:15
Auditorium 4

Parallel Session for Pediatrics The sick pediatric liver recipient

Concurrent Oral Abstract Session
14:45 - 16:15
Auditorium 6

Donation after Cardiac Death and Outcomes

Chairs:
Jeroen de Jonge, Rotterdam, Netherlands
Andrea Schlegel, Birmingham, United Kingdom

O-016 Donation after cardiac death liver transplantation with normothermic regional perfusion and hypothermic machine perfusion: follow-up of the first Italian series
Riccardo De Caris, Milan, Italy

O-017 Brain-death-donors and cardiac-death-donors: evaluation of liver inflammation and cytolysis on perfusion fluids during cold ischemia time
Daniele Dondossola, Milan, Italy

O-018 Changes in graft gene expression contribute to coagulopathy in uDCD liver transplantation
Amelia Hessheimer, Barcelona, Spain

O-019 Development and validation of nomogram to predict primary non function in liver transplant recipients using donation after cardiac death donor graft
Zhiyong Guo, Guangzhou, China

O-020 Comparative study of the evolution under normothermic machine perfusion of type 2 DCD grafts discarded for transplantation and type 3 transplanted DCD grafts
Mihai-Calin Pavel, Barcelona, Spain

Page 28 / 68
Scientific Programme

O-021 Combined liver-kidney transplantation (CLKT) with delayed approach kidney transplantation (KT) enables similar patient survival as liver transplantation alone (LTA): propensity score-based comparison
Burcin Ekser, Indianapolis, United States

O-022 Transplantation of DCD livers leads to a higher rate of post-transplant acute kidney injury, but not chronic kidney disease when compared to NDD or LDLT
Shuet Fong Neong, Toronto, Canada

O-023 Prioritizing high MELD patients decreased patient waiting time without change in survival: an analysis of 575 consecutive recipients from a single center experiences
David Victor, Houston, United States

O-024 Transthyretin defective livers for domino liver transplantation (DLT). The 2017-year Domino Liver Transplant Register (DLTR) perspective. Should novel anti-amyloidosis drugs be considered post-DLT?
Carl Jorns, Stockholm, Sweden

Concurrent Oral Abstract Session
14:45 - 16:15
Auditorium 7

Donor Selection Criteria / Patient Selection / Organ Allocation

Chairs:
John Roberts, San Francisco, United States
Abraham Shaked, United States

O-025 Evaluation of a portable micro-spectrometer for real-time assessment of liver graft macrosteatosis
Nicolas Golse, Villejuif, France

O-026 Exploring the enigma of pre-transplant donor-specific antibody expression in the context of organ shortage in liver transplantation
John Chen, Adelaide, Australia

O-027 Performance of Donor Risk Index in the MELD era
Allison Kwong, Stanford, United States

O-028 Receiving hypertensive donor has an inferior prognosis in simultaneous liver kidney transplantation recipient
Weiqiang Ju, Guangzhou, China

O-029 Effects of disease-specific approach on liver transplant volumes
Steven Hanish, Baltimore, United States

O-030 Size mismatch in deceased whole liver transplantation and its impact in graft survival
Martin Montenovo, Seattle, United States

O-031 High graft and patient survival with ABO incompatible liver transplantation utilizing a standardized protocol
Simone Strasser, Sydney, Australia

O-032 Liver transplantation using pediatric versus adult donor grafts in adult recipients
Scientific Programme

O-033 Effectiveness and safety of octogenarian donors in liver transplantation: propensity score matched study from two Italian liver transplant centers
Grazia Conte, Ancona, Italy

Concurrent Oral Abstract Session
14:45 - 16:15 Auditorium 8

Basic Science / Translational Research Trends in basic/translational science: Moving the field forward through innovative approaches

Chairs:
Luc van der Laan, Rotterdam, Netherlands
Kuang-Tzu Huang, Kaohsiung, Taiwan, Republic of China

O-034 Differences in the colon microbiome between patients with and without recurrence of primary sclerosing cholangitis
Thijmen Visseren, Rotterdam, Netherlands

O-035 In vivo and In vitro PPAR-y activation decreases M1-macrophage polarization and improves liver ischemia reperfusion injury
Markus Selzner, Canada

O-036 Rictor mTORC2 signaling protects ischemic liver injury by targeting both liver parenchymal and non-parenchymal cells
Haoming Zhou, Los Angeles, United States

O-037 Short- and long-term outcomes of AAV-mediated TIMP-1 gene therapy in hepatic ischemia and reperfusion injury
Sergio Duarte, Los Angeles, United States

O-038 Expression profile analysis of circular RNAs in early allograft dysfunction after liver transplantation
Kun Wang, Hangzhou, China

O-039 Immune surveillance vs. immune escape: strategic release of exosomal microRNAs in hepatocellular carcinoma
Toshiaki Nakano, Kaohsiung, Taiwan, Republic of China

O-040 Re-endothelialization of liver xenografts utilizing human endothelial cells
Wessam Hassanein*, Baltimore, United States

O-041 Bile duct regeneration: characterization of human bile duct derived organoids
Kseniia Burka, Rotterdam, Netherlands

O-042 CCR5(+) NK cell exhaustion facilitates tumor recurrence after liver transplantation via PD-L1/TLR4 pathway
Xin Xiang Yang, Hong Kong, Hong Kong

Poster Sessions
16:15 - 17:00 Poster Area

Poster Session: Surgical Videos 3
Scientific Programme

**eP-007**  Ex-situ resection with liver auto-transplantation for locally advanced cholangiocarcinoma causing secondary Budd-Chiari syndrome: an occam’s razor?
Ashwin Rammohan, Chennai, India

**eP-008**  Useful technical tips in pure laparoscopic donor right heptectomy

**eP-009**  Pure 3D laparoscopic donor right hemihepatectomy in the case with anatomic variation of portal vein and bile duct
Kwang-Woong Lee, Seoul, Korea, Republic of

Poster Sessions  
16:15 - 17:00  

**Poster Round I, Session 3**

For a complete list of posters please see Poster Round I, Session 1:

Click on Poster Round I, Session 1, taking place on Wednesday, 23.05.2018 18:15-19:00

Viewing Sessions of Poster Round I are:
Session 1 - Wednesday, 23.05.2018, 18:15-19:00
Session 2 - Thursday, 24.05.2018, 10:00-10:45
Session 3 - Thursday, 24.05.2018, 16:15-17:00

Concurrent Oral Abstract Session  
17:00 - 18:30  

**Machine Perfusion**

Chairs:  
Chris Watson, Cambridge, United Kingdom  
Luciano de Carlis, Milan, Italy

**O-043**  The effect of normothermic machine perfusion after cold storage in liver transplantation: a multicentre prospective clinical trial  
Carlo Domenico Lorenzo Ceresa, Oxford, United Kingdom  
17:00

**O-044**  Evaluation of bile production and bile quality as a prognostic marker during normothermic ex vivo liver perfusion  
Dagmar Kollmann, Vienna, Austria  
17:10

**O-045**  Factors predicting viability achievement on discarded donor livers submitted to extra-corporeal machine perfusion  
Yuri Boteon, Birmingham, United Kingdom  
17:20

**O-046**  Pharmacological defatting of steatotic human livers using a novel perfusion solution during normothermic machine perfusion  
Yuri Boteon, Birmingham, United Kingdom  
17:30

**O-047**  Impact of ELAD C3A conditioned medium enhanced perfusate fluid on the function recovery of high-risk donor livers during normothermic machine perfusion  
Lorraine Wallace, Birmingham, United Kingdom  
17:40
Scientific Programme

O-048 The first series of ischemia-free liver transplantation in human
Xiao-Shun He, Guangzhou, China

O-049 Normothermic machine perfusion for liver preservation: tissue ATP depletion as a marker of liver viability
Prakash Vel Sankhya, Coimbatore, India

O-050 Normothermic ex vivo liver perfusion prevents platelet sequestration and platelet induced sinusoidal cell injury in the liver when compared to static cold storage
Dagmar Kollmann, Vienna, Austria

O-051 The use of LiMAX for evaluating donor livers on normothermic machine perfusion
Ivo Johannes Schurink, Rotterdam, Netherlands

Concurrent Oral Abstract Session
17:00 - 18:30
Auditorium 2

LICAGE Parallel Abstract Session II: Anesthesia / Critical Care Medicine

Chairs:
Annabel Blasi, Barcelona, Spain
Michael Kaufman, Burlington, United States

O-061 Spectral Doppler assessment of carotid arterial blood flow dynamics can reliably measure instantaneous cardiac output and fluid responsiveness during liver transplantation
Nandakumar Krishnaraju, New Delhi, India

O-062 Diastolic dysfunction (DD), measures of ventricular repolarization, and filling pressures in deceased donor liver transplant recipients (DDLT)
Jana Hudcova, Burlington, United States

O-063 Early postoperative acute kidney injury among pediatric liver transplant recipients
Helin Sahinturk, Ankara, Turkey

O-064 Risk factors for revere ACLF and death in cirrhotic patients hospitalized with bacterial infection
Tirzah Secundo, Campinas, Brazil

O-065 Association between postoperative hyperglycemia and cytomegalovirus infection in cytomegalovirus seropositive liver transplant recipients
Kangha Jung, Seoul, Korea, Republic of

O-066 Evaluating in cirrhotics with refractory vasoplegia the effect of methylene blue (crumbs) - a randomized controlled trial
Thirumurugan Karthik Ponnappan, New Delhi, India

O-067 Postoperative tracheal extubation after pediatric liver transplantation
Helin Sahinturk, Ankara, Turkey

O-068 Our experience with regional anesthesia in fast tracking pediatric patients undergoing living related liver transplantation
Vijay Shankar, New Delhi, India
The 2018 Annual ILTS Meeting,
May 23-26, 2018,
Lisbon, Portugal

Scientific Programme

O-069  Prolonged QTc interval and risk of severe postreperfusion syndrome in liver transplantation
Kyoung-Sun Kim, SEOUL, Korea, Republic of

Others
17:00 - 18:30  Auditorium 3

Parallel Session for Pediatrics Debates in current pediatric practice

Chairs:
Jan Lerut, Brussels, Belgium

Centralisation of pediatric liver transplant services is essential for optimal outcomes
João Seda-Neto, Sao-Paolo, Brazil
Manuel Rodriguez, Salt Lake City, United States

Long-term graft fibrosis: Is it goodbye for immunosuppression withdrawal?
Deirdre Kelly, Birmingham, United Kingdom
Nazia Selzner, Toronto, Canada

Reducing waiting list mortality in children: LDLT, not more variant & marginal grafts is the answer
Mohamed Rela, Chennai, India
George V. Mazariegos, Pittsburgh, United States

Others
17:00 - 18:30  Auditorium 4

Parallel Session for Pediatrics Debates in current pediatric practice

Concurrent Oral Abstract Session
17:00 - 18:30  Auditorium 6

Immunosuppression and Tolerance Induction

Chairs:
Geoffrey McCaughan, Sydney, Australia
Yuan Zhai, Los Angeles, United States

O-052  Randomised study of steroid free immunosuppression with basiliximab induction vs standard triple drug immunosuppression in adult live donor liver transplantation (LDLT). CTRI/2017/08/009508
Manikandan Kathirvel, Kochi, India

O-053  Tacrolimus and single intra-operative high-dose of r-atg induction vs. Tacrolimus monotherapy as immunosuppression in liver transplantation: one-year results of an investigator-driven, prospective, randomized, controlled trial
Samuele Iesari, Brussels, Belgium
Scientific Programme

O-054  Outcome of tailored rituximab-based desensitization protocol without local infusion therapy for ABO incompatible adult living donor liver transplantation  
Koji Natsuda, Seoul, Korea, Republic of

O-055  Dual function of IRF1/IRF4 on dendritic cells during mouse liver transplant model  
Guangxiang Gu, Shanghai, China

O-056  Optimization of induction immunosuppression in simultaneous liver kidney transplantation: Is anything more than steroids necessary?  
Trevor Reichman, Richmond, United States

O-057  Impact of liver perfusate natural killer cellular subset from deceased brain donors on acute cellular rejection prediction after liver transplantation: COX proportional regression analysis  
Duilio Pagano, Palermo, Italy

O-058  De-novo use of extended realeased Tacrolimus (EnvarsusR) after OLT  
Thomas Soliman, Vienna, Austria

O-059  How to optimize early immunosuppression after liver transplantation for ACLF 3 patients?  
Francois Faitot, Strasbourg, France

O-060  Effects of donor-recipient combinational CYP3A5 genotypes on tacroimus dosing in Chinese DDLT adult recipients  
Dexi Chen, Qingdao, China

Concurrent Oral Abstract Session
17:00 - 18:30  
Auditorium 7

Malignancies

Chairs:  
Martina Gambato, Padova, Italy  
Taizo Hibi, Tokyo, Japan

O-070  Prognostic role of exosomal miR-1290 in hepatocellular carcinoma recurrence after curative treatments  
Yin Fan Lam, Hong Kong, Hong Kong

O-071  Bridging therapies are not detrimental in patients with hepatocellular cancer waiting for liver transplant: a propensity score analysis  
Quirino Lai, Brussels, Belgium

O-072  Long-term risk of solid organ de novo malignancies after liver transplantation: a French National study on 11226 patients  
Mario Altieri, CAEN, France

O-073  Expression of tumor stem cell marker EpCAM in patients undergoing transplantation for hepatocellular carcinoma and its relationship between tumor recurrence  
Zhao Li, beijing, China
Scientific Programme

O-074  Assessing the risk of de novo neoplasms after liver transplantation: role of pre-transplant hepatocellular carcinoma
Sarah Shalaby, Padua, Italy  17:40

O-075  The influence of initial tumor burden and transplant wait times on post-transplant outcomes after successful down-staging of hepatocellular carcinoma
Neil Mehta, San Francisco, United States  17:50

O-076  Proteomic predictors of HCC recurrence in liver transplant patients with tumors beyond Milan criteria
Mamatha Bhat, Toronto, Canada  18:00

O-077  Liver tumor with high FDG-PET uptake predicts unfavorable tumor histology in explanted liver of living donor liver transplant recipients
Louis Leong Liung Ling, Kaohsiung, Taiwan, Republic of China  18:10

O-078  Ischemia-reperfusion injury and the risk of hepatocellular carcinoma recurrence after deceased donor liver transplantation
Michal Grat, Warsaw, Poland  18:20

Concurrent (ELITA)
17:00 - 18:30  Auditorium 8

ELITA interactive session

Chairs:
Christophe Duvoux, Créteil, France
Krzysztof Zieniewicz, Warsaw, Poland

A success of the ELTR in the last 30 years
Vincent Karam, Villejuif, France  17:00

Trends in liver transplantation for primary biliary cholangitis in Europe over the last three decades
Herold Metselaar, Rotterdam, Netherlands  17:20

Impact of DAA on liver transplantation: major effects on the evolution of indications and results. A study based on the ELTR registry
Luca Belli, Milan, Italy  17:35

How to apply for ELITA-ELTR study
Wojciech Polak, Rotterdam, Netherlands  17:50

Round table discussion  18:10
Friday, 25 May 2018

Vanguard Sessions
06:30 - 07:30
Restaurant CCL

Vanguard Debate Session

Chairs:
Taizo Hibi, Tokyo, Japan
Tommaso Di Maira, Valencia, Spain

06:30
Who should receive a marginal quality liver: the low MELD or the high MELD patient?
Eleonora De Martin, Villejuif, France
Kelvin KC Ng, Pokfulam, Hong Kong

06:50
Bigger is Better: Fewer high volume centers serve populations better than multiple low volume centers
Carmen Vinaixa, Valencia, Spain
Irene Scalera, Birmingham, United Kingdom

07:10
ECMO as a Bridge to OLT (Other than in Hepatopulmonary Syndrome) – Pro/Con
Michael Kaufman, Burlington, United States
Ryan Chadha, Jacksonville, United States

Plenary Abstract Session
08:00 - 10:00
Auditorium 1

Plenary Abstract Session I

Chairs:
Jan Lerut, Brussels, Belgium
Chung Mau Lo, Hong Kong

O-079
Pivotal pre-clinical randomized trial of SRBAL in post-hepatectomy ALF pigs
Harvey Chen, Rochester, United States

O-080
Mild to moderate aortic insufficiency in liver transplantation: prevalence, perioperative management and short-term outcomes
Kyota Fukazawa, Seattle, United States

O-081
Characterization of the FAH/RAG2 double-knockout pig
Erek Nelson, Rochester, United States

O-082
Normothermic regional perfusion (NRP) for DCD liver transplantation in the UK: better graft survival with no cholangiopathy
Chris Watson, Cambridge, United Kingdom

O-083
Class II epitope / eplet mismatch predicts de novo DSA formation and acute cellular rejection after liver transplantation
Chandrashekhar Kubal, Indianapolis, United States
The 2018 Annual ILTS Meeting,  
May 23-26, 2018,  
Lisbon, Portugal

### Scientific Programme

<table>
<thead>
<tr>
<th>Session Code</th>
<th>Title</th>
<th>Speaker</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>O-084</td>
<td>Donor biliary complications in high-volume living-donor liver</td>
<td></td>
<td>09:00</td>
</tr>
<tr>
<td></td>
<td>transplantation center in Korea</td>
<td></td>
<td></td>
</tr>
<tr>
<td>O-085</td>
<td>Ischemia-free liver transplantation in pigs: ischemia reperfusion</td>
<td>Zhiyong Guo, Guangzhou, China</td>
<td>09:12</td>
</tr>
<tr>
<td></td>
<td>injury is avoidable?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>O-086</td>
<td>Proposal for a worldwide usable core for the prediction of hepatocellular</td>
<td>Quirino Lai, Brussels, Belgium</td>
<td>09:24</td>
</tr>
<tr>
<td></td>
<td>cancer recurrence and intention-to-treat survival after transplantation:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>a west-east analysis on 1,903 patients</td>
<td></td>
<td></td>
</tr>
<tr>
<td>O-087</td>
<td>The feasibility of laparoscopic living donor right hepatectomy compared</td>
<td>Giovanni Perricone, Milano, Italy</td>
<td>09:36</td>
</tr>
<tr>
<td></td>
<td>to open surgery including 100 laparoscopic cases</td>
<td></td>
<td></td>
</tr>
<tr>
<td>O-088</td>
<td>Outcome of liver transplant candidates “delisted” after successful</td>
<td></td>
<td>09:48</td>
</tr>
<tr>
<td></td>
<td>treatment of HCV infection</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Poster Sessions**

10:00 - 10:45

**Poster Round II, Session 1: Acute Liver Failure**

<table>
<thead>
<tr>
<th>Session Code</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-242</td>
<td>Living donor re-transplantation for repeated acute liver failure</td>
<td>Volkan Ince, Malatya, Turkey</td>
</tr>
<tr>
<td>P-243</td>
<td>Acute-on-chronic liver failure (ALCF) and liver transplantation</td>
<td>Lucas Nacif, Sao Paulo, Brazil</td>
</tr>
</tbody>
</table>

**Poster Round II, Session 1: Alcoholic Liver Diseases / NASH / NAFLD**

<table>
<thead>
<tr>
<th>Session Code</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-244</td>
<td>Combined liver transplantation and sleeve gastrectomy for end-stage</td>
<td>Mario Vilatoba, Ciudad de</td>
</tr>
<tr>
<td></td>
<td>liver disease in a morbid obese patient. First Mexican case-report</td>
<td>Mexico, Mexico</td>
</tr>
<tr>
<td>P-245</td>
<td>Alcoholic liver disease versus virus hepatitis in living donor liver</td>
<td></td>
</tr>
<tr>
<td></td>
<td>transplantation</td>
<td></td>
</tr>
</tbody>
</table>

**Poster Round II, Session 1: Anesthesia / Critical Care Medicine**

<table>
<thead>
<tr>
<th>Session Code</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-246</td>
<td>Hyponatremia is associated with lower risk of PVT in liver transplant</td>
<td>Dmitri Bezinover, Hershey,</td>
</tr>
<tr>
<td></td>
<td>candidates independent of liver disease severity</td>
<td>United States</td>
</tr>
</tbody>
</table>
The 2018 Annual ILTS Meeting,
May 23-26, 2018,
Lisbon, Portugal

Scientific Programme

P-247  Evaluation of TEG6s thromboelastography device in patients undergoing liver transplantation
Lasitha Abeysundara, London, United Kingdom

P-248  Thrombocytopenia after liver transplantation - predictors of delayed recovery and its impact on outcome after liver transplantation
Akila Rajakumar, Chennai, India

P-249  Reduction in post-orthotopic liver transplant (OLT) extubation times following the implementation of a fast track extubation initiative: single centre experience of 285 consecutive cases
Ravi Bhatia, London, United Kingdom

P-250  Systolic anterior motion of mitral valve after reperfusion in liver transplantation
Uzung Yoon, Philadelphia, United States

P-251  Experience with epidural placement on immunosuppressed patients status-post transplant
Samantha Yeap, Indianapolis, United States

P-252  Serum cytokine profiles associated with acute kidney injury in patients underwent living donor liver transplantation

P-253  Incidence of acute kidney injury following liver transplantation
Zeynep Ersoy, Ankara, Turkey

P-254  Exchange transfusion using autotransfusion for rapid correction of hyperkalemia in liver transplantation
Uzung Yoon, Philadelphia, United States

P-255  Preoperative glycosylated haemoglobin (HbA1c) and postoperative morbidity and mortality in liver transplant patients: a retrospective study
Mohd Qurram Parveez, New Delhi, India

P-256  Perioperative outcome in patients with hepatorenal syndrome undergoing living donor liver transplantation

P-257  Metabolic acidosis during liver transplantation especially during reperfusion in patient with ESLD and hyponatremia
Mitsuru Nakatsuka, Richmond, United States

P-258  Acute heart failure after orthotopic liver transplantation: a case series
Sonal Sharma, Hershey, United States

P-260  Successful LDLT in a case of mean pulmonary arterial pressure of 52 mmHg

P-261  Comparison of mixed venous oxygen saturation and central venous oxygen saturation in patients undergoing living donor liver transplantation
Soeun Jeon, Busan, Korea, Republic of

P-262  Mediastinal shift and cardiac arrest caused by a mucus plug despite same sided pneumothorax resulting in primary graft failure of an orthotopic liver transplant
Vivienne Hannon, London, United Kingdom

Poster Sessions
10:00 - 10:45

Poster Round II, Session 1: Basic Science / Translational Research

Page 38 / 68
### Scientific Programme

| P-263 | Carbon monoxide can ameliorate hepatic warm ischemia-reperfusion injury in a preclinical miniature swine model |
|       | Takahiro Murokawa, Kagoshima, Japan |

| P-264 | Association between subclinical low serum 25(OH)D in donors and fatty liver disease in recipients after living donor liver transplantation |
|       | King-Wah Chiu, Kaohsiung, Taiwan, Republic of China |

| P-265 | Relevance of steatosis in the regulation of cortisol levels in livers subjected to hepatic surgery |
|       | Elsa Negrete-Sánchez, Barcelona, Spain |

| P-266 | Generation of chemically derived hepatic progenitor from human adult liver |
| P-268 | The role of HNF1A-AS1 in the development of hepatocellular carcinoma |
| P-269 | Human marrow mesenchymal stem cells promote hepatocarcinogenesis by promoting the development of tumor stem cells |
| P-270 | Hepamine - a liver disease microarray database, visualization platform and data-mining resource |
|       | Timo Itzel, Mannheim, Germany |

| P-271 | Targeting PLK1 via nanoparticle drug delivery system to treat hepatocellular carcinoma |
| P-272 | Post-reperfusion bile pH and glucose in deceased donor liver transplant |
|       | Rohit Guarav, Cambridge, United Kingdom |

| P-273 | Novel self-assembling nanoparticle from irinotecan shows high anti-tumor efficacy in pancreatic cancer |
|       | Linshi Zhang, Hangzhou, China |

| P-274 | ITGA3 promotes proliferation and cell cycle progress in intrahepatic cholangiocarcinoma |
| P-275 | An optimized near infrared fluorescent probe for tracking the synthesis and degradation of native albumin in complex biological systems |
| P-276 | The role of GCNT3 in pancreatic cancer |
| P-277 | Alterations in expression of hepatocellular bile salt transporters after warm ischemic injury in rats |
| P-278 | FK506 accelerates CoCl2 - induced cytotoxicity via ER stress pathway in HepG2 cells |
|       | Sang Young Chung, Gwangju, Korea, Republic of |

| P-279 | The MELD score is positively correlated with NLR in association with poor prognosis and low CD34 and GATA2 levels in HCC patients after liver transplantation |
| P-280 | LRP12 is associated with malignancies in liver cancer |
|       | Yingcai Yan, Hangzhou, China |

| P-281 | Proliferation related EMT pathway induces the resistance of pancreatic cancer to gemcitabine |
|       | Jiarong Zhou, Hangzhou, China |

| P-282 | Low expression of the ANCR is associated with poor survival in hepatocellular carcinoma |
| P-283 | RAD-21 is associated with malignancies in liver cancer |

| P-285 | The histidine triad nucleotide-binding protein can improve gemcitabine apoptotic effect in pancreatic cancer |
**Scientific Programme**

**Poster Round II, Session 1: Immunosuppression and Tolerance Induction**

**P-288** Clinical outcomes of late conversion to once-daily tacrolimus after liver transplant  
Deok Gie Kim, Seoul, Korea, Republic of

**P-289** Safety of reconversion to calcineurin inhibitor (CNI) based immunosuppression in liver transplant recipients who had been converted to everolimus for post-transplant renal impairment  
Murat Dayangac, Istanbul, Turkey

**P-290** Association of acute - chronic rejection and initial immunosuppressant therapy on patients who received liver transplantation from deceased donor

**P-292** Monotherapy immunosuppressive treatment with prograf in orthotopic liver transplantation: a single center experience

**Poster Round II, Session 1: Viral Hepatitis**

**P-295** Recurrent hepatitis C antiviral treatment - a real life study at a Brazilian transplant unit  
Leticia Pisoni Zanaga, Campinas, Brazil

**P-296** Prevalence of hepatitis C in Southeast China: a hospital-based study

**P-297** The association between donor genetic variations in one-carbon metabolism pathway genes and hepatitis B recurrence after liver transplantation

**P-298** Treatment naive hepatitis C cirrhosis: selected scoring systems and survival in a prison population  
Patrick Naeger, Galveston, United States

**P-300** The study of virological and immunologic factors of the progression of chronic viral hepatitis delta in the Kazakh population

**Poster Round II, Session 1: Donation after Cardiac Death**

**P-301** A successful case of liver transplantation in an adult with congenital hepatic arteriovenous fistulae associated cardiac dilatation and heart failure  
Beicheng Sun, Nanjing, China
Scientific Programme

P-302  First type 2 DCD human liver graft transplanted after normothermic machine perfusion. The improvement that leads to transplantation
Mihai-Calin Pavel, Barcelona, Spain

P-303  Clinical factors affecting early acute liver allograft rejection after DCD liver transplantation

Poster Sessions
10:00 - 10:45

Poster Round II, Session 1: Machine Perfusion

P-304  Ischemia-free liver transplantation for fatty liver allografts in human
Weiqiang Ju, Guangzhou, China

P-305  Release of hyaluronan fragments during ex vivo perfusion of human liver

Poster Round II, Session 1: Donor Selection Criteria/patient selection/organ allocation

P-307  Incidence of hepatic artery anomaly in the liver procurement procedure in State University of Campinas
Ilka Boin, Campinas, Brazil

P-308  Age and area of study does not influence undergraduates' opinions and awareness about organ donation
Ilka Boin, Campinas, Brazil

P-309  Novel surgical technique and efficacy analysis of donor pancreas without vascular reconstruction in pancreas transplantation
Carlos Florez Zorrilla, Ciudad de Mexico, Mexico

P-310  Donor hypernatremia is not associated with primary graft dysfunction in orthotopic liver transplantation
Carlos Florez Zorrilla, Ciudad de Mexico, Mexico

P-311  Simultaneous liver-kidney transplant using HCV RNA-positive donor in HCV RNA-negative recipient
Behnam Saberi, Baltimore, United States

P-312  Evolution and impact of obesity in patients on the liver transplant waiting list
Mathilde Favre, Lille, France

P-313  Comparison study of outcomes of deceased donor liver transplantation before and after Korean model for end-stage liver disease (MELD) system - a single center experience
Gyu-Seong Choi, Seoul, Korea, Republic of

P-314  A review of discarded organs from deceased donors in South Korea

P-316  Child-to-adult deceased donor liver transplantation: clinical application and practical considerations

P-317  The changes of pediatric liver transplantation in seoul national university hospital according to the changes of allocation system
Scientific Programme

P-318 Changing hepatic grafts allocation, from chronological order to MELD based: repercussion upon the panel of aetiologies and on waiting-list mortality in a South-Eastern Brazilian centre
Agnaldo Soares Lima, Belo Horizonte, Brazil

P-319 Selection criteria and prognostic factors for liver transplantation
Lucas Nacif, Sao Paulo, Brazil

P-320 Donor one-carbon metabolism genes’ single nucleotide polymorphisms affect the susceptibility of cancer recurrence after liver transplantation
Chao Wang, Hangzhou, China

P-321 Hypernatremic donors, are they really marginal grafts for liver transplantation?

P-322 A study comparing Institut Georges Lopez-1 preservation solution to the university of Wisconsin preservation solution in liver transplantation

P-324 Liver transplantation using an injured liver which has large subcapsular hematoma

Poster Sessions
10:00 - 10:45
Poster Area

Poster Round II, Session 1: Living Donor

P-325 ABO-incompatible living donor liver transplantation using a desensitizing protocol without local graft infusion therapy and splenectomy
Tae Beom Lee, Yansan-si, Korea, Republic of

P-326 Is necessary ductoplasty during reconstruction of two adjacent bile duct in right lobe living donor liver transplantation? Cluster with mucosal eversion technique
Joo Dong Kim, Daegu, Korea, Republic of

P-327 Beyond the comfort zone: a residual liver volume less than 30% after right hepatectomy in living liver donors
Abu Bakar Hafeez Bhatti, Islamabad, Pakistan

P-328 A combined rescue strategy for the treatment of early post-operative portal vein thrombosis following living donor liver transplantation with simultaneous splenectomy

P-329 Hepatic hemodynamic after right lobe living donor liver transplantation with middle hepatic vein
Oleg Kotenko, Kiev, Ukraine

P-330 Safe optimization of GRWR and remnant liver volume in right lobe LDLT: interlobar vascular plane is not a watershed
Thiagarajan Srinivasan, Gurgaon, India

P-331 Middle hepatic vein reconstruction using ePTFE grafts in right lobe living donor liver transplantation
Sanjay Goja, Gurgaon, India

P-332 Randomized trial of polytetrafluoroethylene graft vs native recipient portal vein for middle hepatic vein reconstruction in right lobe living donor liver transplantation (LDLT)
Madhu Srinivasan Durairaj, Kochi, India

P-333 Donors for LDLT with hepatosteatosis
Scientific Programme

P-334  Urgent ABO-incompatible living donor liver transplantation for patients with decompensated liver disease: report of four cases

P-335  Is pre-operative biliary imaging mandatory in all living liver donor assessment? A prospective study
Noushif Medappil, Kochi, India

P-336  Comparative study of pure laparoscopic donor right hemihepatectomy and open donor right hemihepatectomy in patients with separate right anterior and right posterior portal veins
Jeong-Moo Lee, Seoul, Korea, Republic of

P-337  Middle hepatic drainage with end to side anastomoses with ringed PTFE in LDLT
Hyoung Tae Kim, Daegu, Korea, Republic of

P-338  Experience of portal pressure and portal flow measurement during living donor liver transplantation

P-339  Laparoscopic-hand assisted living donor right hepatectomy: case series of a single center in USA
Paulo Martins, Worcester, United States

P-340  Hydrojet: a safe, effective device for parenchymal transection in donor hepatectomy for living donor liver transplantation
Anand Ramamurthy, Chennai, India

P-341  Advancement in perioperative outcomes of living donors in pure laparoscopic right hepatectomy

P-342  Comparison of hemoglobin levels via measured with pulse co-oximeter and with lab test during living donor hepatectomy
Yusuf Ziya Colak, Malatya, Turkey

P-343  Liver biopsy results in potential donor evaluation in living related liver transplantation
Ebru H. Ayvazoglu Soy, Ankara, Turkey

P-344  Safety of living donors in liver transplantation in a low volume transplant center
Seong-Hwan Chang, Seoul, Korea, Republic of

P-345  Liver graft features in adult living donor liver transplantation

P-346  Modified venous patch method for venous reconstruction in liver transplantation using right robe

P-347  Extraanatomic arterial reconstruction using great saphenous vein
Yang-Seok Koh, Jeonnam, Korea, Republic of

P-348  ABO incompatible living donor liver transplantation for huge hepatomegaly due to polycystic liver disease
Je Ho Ryu, Yang-san, Korea, Republic of

P-349  Anastomosis bile duct and portal anomaly in living donor liver transplantation
Kwangsik Chun, Daejeon, Korea, Republic of
Scientific Programme

P-350  Is there a magic weight number to improve outcome in living related pediatric liver transplants? Experience from a high volume centre  
Neelam Mohan, Gurgaon, India

P-351  Successful outcome of ABO Incompatible pediatric living related liver transplant using the standard immunosuppression  
Neelam Mohan, Gurgaon, India

P-352  Clinical features, laboratory findings and prognosis in fulminant Wilson’s disease  
Zeren Baris, Ankara, Turkey

P-354  Perioperative anesthetic management for liver transplantation in child with unrepaired large secundum atrial septal defect (ASD)  
Dritan Prifti, Cleveland, United States

P-355  Vascular graft for inferior vena cava reconstruction in living donor liver transplantation: two case report  
Marek Szymczak, Warsaw, Poland

P-356  Abernethy syndrome presenting with hepatopulmonary syndrome, hematuria and multiple FNHs  
Rasim Farajov, Izmir, Turkey

P-357  Successful liver transplantation for severe cholestatic liver disease in a girl with DOCK8 deficiency following allogeneic bone marrow transplantation  
Sandra Maria Gonçalves Vieira, Porto Alegre, Brazil

P-358  CD ratio may predict tacrolimus metabolism profile after pediatric liver transplantation  
Vivekanandan Shanmugam, Coimbatore, India

P-359  Sequential liver & kidney transplant from a single live donor for primary hyperoxaluria  
Deniz Balci, Ankara, Turkey

Poster Sessions
10:00 - 10:45

Poster Round II, Session 1: Outcomes / Complications

P-361  Graft regeneration and functional recovery in patients with early allograft dysfunction after living donor liver transplantation

P-362  The role of serum cytokine profiles on early allograft dysfunction development in living donor liver transplantation

P-363  Health-related quality of life and psychosocial parameters in patients awaiting liver transplantation surgery: a service evaluation at the Royal Free Hospital  
Clare Morkane, London, United Kingdom

P-364  Biliary troubleshooting in living donor hepatectomy

P-365  The inflammatory and nutritional markers as the predictors for the recurrence of hepatocellular carcinoma after liver transplantation  
Yoon Bin Jung, Seoul, Korea, Republic of
P-367 Early biliary complications after different methods of end-to-end biliary anastomosis in liver transplant recipients
Agnieszka Jóźwik, Warsaw, Poland

P-369 Wait-and-watch approach in patients with anastomotic biliary strictures after orthotopic liver transplantation: is treatment always necessary?
Camille Besch, Strasbourg, France

P-370 Liver transient elastography following liver transplantation
Lucas Nacif, Sao Paulo, Brazil

P-371 Comprehensive validation of different clinical prediction models on short- and long-term outcome following orthotopic liver transplantation
Georg Lurje, Aachen, Germany

P-372 Long-term outcomes of liver transplantation in patients with pre-transplant renal dysfunction treated with induction therapy and delayed reduced de novo once-daily tacrolimus

P-373 Low platelet count after liver transplantation: a predictor of death and graft survival?

P-374 Hepaticojejunostomy for benign disease: long-term stricture rate and management
J.J. Klein, Chicago, United States

P-375 Liver transplantation with portal vein thrombosis - the missing link in optimizing outcome. a case-control study
Palaniappan Kumar, CHENNAI, India

P-376 Compromise between hepatectomy time and blood transfusion after liver transplantation: impact on 90-days mortality

P-377 No need for systemic heparinization during living donor hepatectomy: short-term and long-term outcomes
Joo Dong Kim, Daegu, Korea, Republic of

P-378 Good long term outcome with low recurrence rate in patients with primary sclerosing cholangitis undergoing living donor liver transplantation
Sanjiv Saigal, Gurgaon, India

P-379 Anastomotic bilio-biliary strictures after adult liver transplantation: a retrospective study over 25 years in a single center
Olivier boillot, Lyon, France

P-380 Arterial variation in liver grafts as a risk factor for postoperative hepatic arterial thrombosis in 850 orthotopic liver transplants at the State University of Campinas

P-381 Plasmapharesis as rescue therapy for early graft dysfunction in living donor liver transplantation

P-382 Smoking until liver transplantation is a risk factor for anastomotic biliary stricture in duct to duct biliary reconstitution in the Meld era

P-383 Survival analysis after adult living donor liver transplantation for hepatocellular carcinoma according to Milan criteria

P-384 Tuberculosis and liver transplantation: are we winning?

P-385 Clinical course of hepatic artery thrombosis after living donor liver transplantation using right lobe
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-386</td>
<td>Evaluation of sleep disorders with different methods in cirrhotics waiting on the liver transplantation list: EEG, polysomnography, PSQI, ESS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P-387</td>
<td>Simultaneous cardiothoracic surgery and liver transplantation: a viable option</td>
<td>Christine Myo Bui</td>
<td>Los Angeles, United States</td>
</tr>
<tr>
<td>P-388</td>
<td>Risk factors of graft loss in early allograft dysfunction following liver transplantation</td>
<td>Qinfen Xie</td>
<td>Hangzhou, China</td>
</tr>
<tr>
<td>P-389</td>
<td>The diabetic retinopathy risk in patients with new-onset diabetes after transplantation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P-390</td>
<td>An unusual cause of graft loss in a pediatric liver transplant recipient: fasciola hepatica</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P-391</td>
<td>ABO incompitable liver transplantation, a case report and review of the literature</td>
<td>Deng Feiwen</td>
<td>Foshan, China</td>
</tr>
<tr>
<td>P-392</td>
<td>The impact of pretransplant sarcopenia on short-term liver transplantation outcome: a single-center experience</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P-393</td>
<td>The experience of everolimus combined with tacrolimus in living donor liver transplantation</td>
<td>Sheng-Chih Kuo</td>
<td>Kaohsiung, Taiwan, Republic of China</td>
</tr>
<tr>
<td>P-394</td>
<td>The safe time interval of endoscopic intervention for biliary complications of liver transplantation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P-395</td>
<td>Central pontine myelinolysis after liver transplantation</td>
<td>Angela Strother</td>
<td>Jackson, United States</td>
</tr>
<tr>
<td>P-396</td>
<td>Primary graft dysfunction - D-MELD and MEAF scores as accurate predictors of outcome</td>
<td>João Cardoso</td>
<td>Coimbra, Portugal</td>
</tr>
<tr>
<td>P-397</td>
<td>Cytomegalovirus (CMV) infection following liver transplantation: the influence of CMV on acute rejection and liver fibrosis</td>
<td>Gonca Ozgun</td>
<td>Ankara, Turkey</td>
</tr>
<tr>
<td>P-398</td>
<td>Severe leukopenia in liver transplant recipient: the role of selective splenic artery embolization</td>
<td>Marina Premužić</td>
<td>Zagreb, Croatia</td>
</tr>
<tr>
<td>P-399</td>
<td>Analysis of the safety and efficacy of anti-TNFα biological treatment in liver transplant patients</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P-400</td>
<td>Duct to duct biliary reconstruction in pediatric split liver transplantation</td>
<td>Rasim Farajov</td>
<td>Izmir, Turkey</td>
</tr>
<tr>
<td>P-401</td>
<td>The course of renal disease liver transplant recipient who requiring perioperative dialysis in liver transplantation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P-402</td>
<td>Assessment of cardiovascular immediate post-liver transplant events. analysis of pretransplant risk factors and postransplant evolution</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P-403</td>
<td>Splenic artery steal syndrome in a living donor liver transplant recipient: a case report</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P-405</td>
<td>Metabolic syndrome after liver transplantation: long-term follow up in a prospective cohort</td>
<td>Giacomo Germani</td>
<td>Padua, Italy</td>
</tr>
<tr>
<td>P-406</td>
<td>Does donor liver weight influences liver enzymatic determination immediately after liver transplantation?</td>
<td>Marco Pellicciaro</td>
<td>Rome, Italy</td>
</tr>
</tbody>
</table>
Scientific Programme

P-407  The surgical management and clinical pathological features of post-transplant lymphoproliferative disorder involved in gastrointestinal tract (GI-PTLD)
Xueqin Meng, Hangzhou, China

P-408  Outcomes of deceased donor liver transplantation using marginal graft in single Asian center
Dong-Sik Kim, Seoul, Korea, Republic of

P-409  Natural history of inflammatory bowel disease in patients with a solid organ transplant

P-410  Atypical presentation of zygomycosis in the early post-liver transplant period under fungal prophylaxis
Saliba Faouzi, Villejuif, France

P-411  Liver grafts for transplantation from donors with hypertension: an analysis of the Scientific Registry of Transplant Recipients Database

P-412  Ecuador’s liver journey: a learning curve from a liver transplantation center in a developing country
Sergio Enderica-Gonzalez, Cumbaya, Ecuador

P-413  The experiences of liver transplantation in small volume center

P-414  Single center experience of liver transplantation for polycystic liver disease
Takaaki Kato, Tokyo, Japan

P-415  Elderly donor and gender impact on cumulative survival rates of liver graft recipient in 20 years of experience in Santiago de Compostela (Spain)
Rita Fernandez Garda, Santiago de Compostela, Spain

P-416  Potentially lethal complications following percutaneous transhepatic biliary drainage for biliary complications in liver transplantation

P-417  Simultaneous multiple organ transplantation including liver grafts

P-418  Clostridium difficile infection after liver transplant is associated with poor long term survival

P-419  Emergency liver transplantation strategy for vascular hilar injuries associated with laparoscopic cholecystectomy
Aniroodh Shankar, Dublin, Ireland

P-420  Functional SFS presenting as isolated cholestasis, managed with splenic artery embolisation
Vivekanandan Shanmugam, Coimbatore, India

P-421  Portal vein thrombosis in adult patients with cirrhosis: outcomes of liver transplantation
Daniele Dondossola, Milan, Italy

P-422  Long-term outcome of dilatation and stenting of anastomotic and non-anastomotic biliary strictures after liver transplantation
Bart van Hoek, Leiden, Netherlands

P-423  Fatal idiopathic hyperammonemia after liver transplantation: a case report
Joo Kim, Seoul, Korea, Republic of

P-424  Arterial anastomotic bleeding and median arcuate ligament syndrome inducing hepatic artery thrombosis and salvage liver transplantation
Sun Xiaodong, Changchun, China
Scientific Programme

P-425  Utilization of extracorporeal membrane oxygenation for a severe cardiocirculatory dysfunction recipient in liver transplantation  
Fan Zhongqi, Changchun, China

P-426  Biliary complications in consecutive a hundred cases of liver transplantation

P-427  Surgical Porto-Caval Shunt and liver transplantation: systematic review  
Lucas Nacif, Sao Paulo, Brazil

P-428  Isolated right hepatic vein (RHV) obstruction after piggyback liver transplantation, an infrahepatic terminolateral cavo-cavostomy as a rescue technique to save the graft

P-429  Increase in urine output after portal caval shunting during recipient heptectomy can predict outcomes in liver transplantation in patients with AKI

P-430  Intraoperative hepatic flow and graft survival in ABO-incompatible liver transplantation: a pilot study

P-431  Diagnostic tools for critical illness myopathy in a patient after liver transplantation: a case report

P-432  A case of jaundice with unknown reason after orthotopic liver transplantation  
Aihua Yao, Nanjing, China

P-433  Single center experience of liver transplant for hepatocellular carcinoma with liver donation after citizen's death in China  
Chen Huanwei, Foshan, China

P-434  Treatment of biliary stone and cast after liver transplantation using the Percutaneous Transhepatic Cholangioscopy (PTCS)  
Ju Ik Moon, Daejeon, Korea, Republic of

Poster Sessions
10:00 - 10:45  
Poster Area

Poster Round II, Session 1: Radiology and Pathology

P-435  Manual computed tomography liver volumetry: can it be done faster?  
Kemal Murat Haberal, Ankara, Turkey

P-436  Portal venous flow alterations in the hepatic artery thrombosis following liver transplant  
Nihal Uslu, Ankara, Turkey

P-437  Hepatocellular carcinoma with drug eluting beads trans-artery chemoembolization in living donor liver transplant

P-438  Percutaneous transhepatic treatment of biliary complications in pediatric patients following living donor liver transplantation  
An Ni Lin, Kaohsiung, Taiwan, Republic of China

P-439  Volumetric reevaluation of liver left lateral segment donors, which had previously been incompatible with intraoperative weight findings  
Kemal Murat Haberal, Ankara, Turkey

P-440  Improving patient safety by performing comprehensive noncontrast magnetic resonance (MR) screening in prospective living donor liver transplant (LDLT) surgery donors - looking beyond MRCP
Scientific Programme

P-441  Recurrence of HCV after living donor liver transplantation evaluated by ARFI elastography

Poster Sessions
10:00 - 10:45
Poster Area

Poster Round II, Session 1: Malignancies

P-443  Which way to go, liver resection or liver transplantation for hepatocellular carcinoma in child a liver cirrhosis

P-444  Intrahepatic cholangiocarcinoma in patients undergoing liver transplantation for hepatocellular carcinoma
Murat Dayangac, Istanbul, Turkey

P-446  Functional role of KLHL21 in growth and progression of cholangiocarcinoma
Chen Jian, Hang Zhou, China

P-447  Risk factors of de novo malignancies after liver transplantation

P-448  Role of mTOR inhibitor in liver transplant recipients administering sorafenib for advanced hepatocellular carcinoma recurrence

P-449  Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma recurrence after liver transplantation
Beicheng Sun, Nanjing, China

P-450  Is Liver transplantation for hepatocellular carcinoma with portal vein invasion oncologically justified? A propensity-score matched analysis with hepatic resection
Albert Chi Yan Chan, Hong Kong, Hong Kong

P-451  Video-laparoscopic MW ablation as alternative treatment for HCC patients: safety and efficacy of 891 procedures

P-452  TGFBI promotes the pancreatic cancer cells metastasis to liver through the inflammatory-related epithelial to mesenchymal transition
Huilin Zheng, Hangzhou, China

P-453  SOCS1 regulates hepatocellular carcinoma cell proliferation through G1-S arrest
Wei Zhang, Hangzhou, China

P-454  The impact of ABO-incompatibility on the long-term survival after liver transplantation in patients with hepatocellular carcinoma
Songfeng Yu, Hangzhou, China

P-455  A case of good prognosis after liver transplantation for the HCC presenting initial advanced stage thereafter nodal and pulmonary metastasis but stable for 9 years
Koo Jeong Kang, Daegu, Korea, Republic of

P-456  Adrenergic signaling promotes the metastasis of HCC
Xuanyu Zhang, Hangzhou, China

P-457  STIP1 expression combined with tumor features is associated with the prognosis of hepatocellular carcinoma patients

P-458  β-adrenergic signaling plays a critical role in recurrence and metastasis of hepatocellular carcinoma
Qianwei Ye, Hangzhou, China
Scientific Programme

P-459  Out-of-Milan criteria and worse intention-to-treat results at a large liver transplant (LT) centre

P-460  The correlation between AFP level and Milan criteria as a prognostic factor of HCC recurrence in the group of liver transplants for HCC

P-461  The impact of HCC family history on the prognosis of HCC patients after hepatectomy

P-462  Long-term survival of a patient with urothelial and liver cancers managed by tumor resection, transplantation and adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration
   Zhaobo Liu, Beijing, China

P-464  A multiple myeloma patient with a previous liver transplantation who underwent autologous stem cell transplantation with melphalan: a case report

P-465  Survival outcomes of liver transplantation for hepatocellular carcinoma in patients with normal, high and very high preoperative AFP levels

P-466  Three-years survival in liver transplant recipients with HCC history
   Paria Mahboub, Worcester, United States

P-467  The proliferative efficacy of RAI3 in hepatocellular carcinoma

P-468  Prognostic value of osteosarcoma amplified 9 in hepatocellular carcinoma

P-469  Long-term survival anterior approach right hepatectomy combined with inferior vena cava thrombectomy using trans-diaphragmatic intrapericardial inferior vena cava occlusion: a case report

P-470  Liver transplantation as a valuable treatment for huge hepatocellular carcinoma beyond the hangzhou criteria: a case report
   Qinfen Xie, Hangzhou, China

P-471  Inhibition of autophagy increases the chemo-sensitivity in pancreatic cancer cell lines
   Fan Yang, Hangzhou, China

P-472  The research of molecular mechanism of PDE7A in hepatocellular carcinoma

Poster Sessions
10:00 - 10:45
Poster Area

Poster Round II, Session 1: Late Breaking Abstracts

LB P-064  Analysis of 20 year survival after liver transplantation in children
   Rebeca Sanabria-Mateos, London, United Kingdom

LB P-065  Clinical analysis of impact of intraoperative hepatic blood inflow on acute kidney injury following allogeneic liver transplantation

LB P-066  Posttransplant lymphoproliferative disorder in liver transplant recipients
   Ying Liu, Beijing, China

LB P-067  Salvage therapies for complicated ABO incompatible living donor liver transplantation: a case report for patient with end stage liver cirrhosis and chronic kidney disease
   Sheng-Chih Kuo, Kaohsiung, Taiwan, Republic of China
**Scientific Programme**

**LB P-068**  Complications after liver transplantation for citrullinemia type 1: the role of arginine and nitric oxide  
Carolin Lemoine, Chicago, United States

**LB P-069**  Bending-over backwards for a severe technical challenge: 4th split liver transplant (SLTx) with reno-portal anastomosis for recurrent PVT in a situs inversus (SI) pediatric patient  
Nadiane Paderno, Bergamo, Italy

**LB P-070**  Aging in liver transplant waiting list: disparity between candidates and grafts  
Nadia Daciuk, Florencio Varela, Argentina

**LB P-071**  Early experience of an emerging liver transplant program in Southeast Asia  
Vanessa De Villa, Pasig City, Philippines

**LB P-072**  EBV-positive posttransplant lymphoproliferative disorder in a 1-year old patient with severe co-morbidities after liver transplantation  
Jingyi Liu, Beijing, China

**LB P-073**  Biliary disease caused by cytomegalovirus infection beyonds our past knowledge in liver transplantation patients with biliary complication  
Jian-Rui Zhang, Beijing, China

**LB P-074**  Early and late biliary complications after living and deceased donor liver transplantation  
Tufan Egeli, Izmir, Turkey

**LB P-075**  Outcome of children with extrahepatic biliary atresia who underwent liver transplantation without Kasai-portoenterostomy  
Sergio Assia-Zamora, London, United Kingdom

**LB P-076**  Comparative analysis of using frame and frameless drainage for duct-to-duct anastomosis during living donor liver transplantation  

**LB P-077**  Patency of middle hepatic vein tributaries and right inferior hepatic vein reconstructed with different sized PTFE vascular graft in right lobe living donor liver transplantation  
Sami Akbulut, Malatya, Turkey

**LB P-079**  Do initial coagulation tests reflect blood product consumption during deceased donor liver transplantation (DDLT)?  
Michael Kaufman, Burlington, United States

**LB P-080**  Risk factors for biliary complications after liver transplantation, in the absence of arterial complications  
Agnaldo Soares Lima, Belo Horizonte, Brazil

**LB P-081**  Successful management of de novo acute hepatitis B with entecavir in a patient underwent living donor liver transplantation  
Sami Akbulut, Malatya, Turkey

**LB P-082**  Long-term survival (13 years) after liver-pancreas-kidney combined transplantation and literature review  

**LB P-083**  Placement of an aortohepatic conduit as an alternative to a standard arterial anastomosis in liver transplantation  
Tae-Yong Ha, Seoul, Korea, Republic of

**LB P-084**  Case of liver transplantation in an infant with biliary atresia associated with situs viscerum inversus and other congenital anomalies  
Yordanka Uzunova, Sofia, Bulgaria
Scientific Programme

LB P-085  Erector spinae plane catheters for analgesia post orthotopic liver transplantation
          Siobhan McGuinness, Dublin, Ireland

LB P-086  Pain after liver transplant: a preliminary report of a single center experience

LB P-087  First use of Cytosorb™ during living related liver transplantation in a patient with acute liver failure due to Wilson's disease
          Dana Tomescu, Bucharest, Romania

LB P-088  Isoglycyrrhizinate magnesium decreases the risk of biliary complications after liver transplantation: a retrospective cohort study
          Yuanxing Liu, Hangzhou, China

LB P-089  Liver transplantation for glycogen storage diseases
          Xiaoying Li, Beijing, China

LB P-090  Portal vein arterialization (PVA) can be an option in cases of complete portal thrombosis diagnosed during liver transplantation. A case report

LB P-091  Unusual indications of liver transplantation

LB P-092  Primary biliary cirrhosis recurrence after liver transplantation
          Mangli Zhang, Hangzhou, China

LB P-093  A case of deceased donor liver transplantation using renoportal anastomosis in patients with diffuse portomesenteric thrombosis

LB P-094  Comparison of standard and modified standart organ procurement technique for deceased donors
          Sami Akbulut, Malatya, Turkey

LB P-095  Anastomosis bile duct and portal anomaly in living donor liver transplantation
          Kwangsik Chun, Daejeon, Korea, Republic of

LB P-096  Significant efficacy of apatinib in a HCC patient with lung metastasis after liver transplantation: a case report
          Guo-Ying Wang, Guangzhou, China

LB P-097  Is there any relationship between clinical parameters and histopathologic features of gallbladder specimens obtained living donor donors?
          Sami Akbulut, Malatya, Turkey

LB P-098  ´The quick portocaval shunt´ a prophylaxis against splanchnic hemorrhage during orthotopic liver transplantation
          Ryan Chadha, Jacksonville, United States

LB P-099  Impact of positive donor-specific HLA antibodies (DSA) crossmatch on graft survival in ABO incompatible liver-kidney transplantation: a case report
          Yao-Li Chen, Changhua, Taiwan, Republic of China

LB P-100  Liver preservation with ex-vivo perfusion: a state of the art review

LB P-101  Ex situ in vivo resection of leiomyosarcoma of the inferior vena cava: an anaesthetic challenge

LB P-102  Perioperative anesthetic management of patient with severe aortic regurgitation for orthotropic liver transplant

LB P-103  Percutaneous treatment of biliary leak in living donor liver transplant recipients
          Sadik Server, Istanbul, Turkey
Scientific Programme

LB P-105  Endovascular management of retrohepatic inferior vena cava thrombosis after diseased donor liver transplantation: intravascular thrombolysis followed by stenting - a case report
Rakesh Rai, Mumbai, India

LB P-106  Non-traditional use of transesophageal echocardiography to evaluate hepatic vasculature in orthotopic liver transplantation: review of literature and case report

LB P-107  Early death in adults after orthotopic liver transplantation at department of general, transplant and liver surgery in Warsaw

LB P-108  How should we approach to incidentally detected neuroendocrine tumor during living donor hepatectomy?
Sami Akbulut, Malatya, Turkey

LB P-109  Case report: difficult vascular access in a paediatric third re-do liver transplant patient
Sanjay Agrawal, London, United Kingdom

LB P-110  Elder donor for living liver transplantation in CCH: current status and challenges

LB P-111  Orthotopic liver transplantation for a pediatric patient with very severe hepatopulmonary syndrome
Cong-Huan Shen, Shanghai, China

LB P-112  Multiple combined treatment of acute Hhmoral rejection after abo-comptible liver transplantation
Xin Duan, Hang Zhou, China

Poster Sessions
10:00 - 10:45  Poster Area

Poster Session: Surgical Videos 4

eP-011  Living donor liver transplantation for leiomyosarcoma of inferior vena cava (IVC) causing secondary Budd Chiari syndrome
Palaniappan Kumar, CHENNAI, India

eP-012  Caudate lobectomy combined with portal vein reconstruction using collateral vein for advanced aggressive fibromatosis at the hepatic hilum
Xiangcheng Li, Nanjing, China

Concurrent (ELITA)
10:45 - 12:15  Auditorium 1

Elita Symposium II: Pushing the Limits in Oncology - beyond HCC

Chairs:
Christophe Duvoux, Créteil, France
Roberto Hernandez-Alejandro, Rochester, United States

Hilar cholangiocarcinoma  10:45
Vincent de Meijer, Groningen, Netherlands

Intrahepatic cholangiocarcinoma  11:03
Gonzalo Sapisochin, Toronto, Canada
Scientific Programme

Neuroendocrine tumors 11:21

Colorectal metastasis 11:39
Pal-Dag Line, Oslo, Norway

Vascular liver tumors 11:57
Jan Lerut, Brussels, Belgium

Featured Symposium
10:45 - 12:15
Auditorium 2

ILTS-TTS joint Symposium: Managing the high risk candidate

Chairs:
Nancy Ascher, San Francisco, United States
Patrizia Burra, Padua, Italy

Indications for transplant in acute on chronic liver failure 10:45
Paolo Angeli, Padova, Italy

Patient selection for transplantation based on performance status 11:03
Kymberly Watt, Rochester, United States

The older patient with multiple co-morbidities: when should we say no? 11:21
John Klinck, Cambridge, United Kingdom

Can we use LDLT grafts in high MELD recipients? 11:39
Chung Mau Lo, Hong Kong

When is transplant futile in the critically ill patient? 11:57
Henrik Petrowsky, Zurich, Switzerland

Featured Symposium
10:45 - 12:15
Auditorium 6

Biliary injury and graft fibrosis

Chairs:
Hiroto Egawa, Tokyo, Japan
Valeria Mas, Charlottesville, United States

The impact of ischemic epigenetics on graft survival 10:45
Daniel Maluf, Charlottesville, United States

Biliary injury in liver transplantation - long-term outcome 11:03
Siu Ho Kenneth Chok, HK, Hong Kong

Small Molecules-Big effects: Role of non-coding RNAs in biliary injury 11:21
Luc van der Laan, Rotterdam, Netherlands

Role of oval cell dynamics in biliary fibrosis after LDLT---clues from the animal model 11:39
Xiaobing Liu, Hong Kong
The 2018 Annual ILTS Meeting,
May 23-26, 2018,
Lisbon, Portugal

Scientific Programme

Graft fibrosis: from biology to therapeutics 11:57
Sofia Ferreira Gonzalez, Edinburgh, United Kingdom

Featured Symposium
10:45 - 12:15 Auditorium 7

Viral Hepatitis in Liver Transplantation - the story beyond recurrence

Chairs:
Mark Ghobrial, Houston, United States
Geoffrey McCaughan, Sydney, Australia

HCV HCC - the indication for transplantation? 10:45
Martina Gambato, Padova, Italy

HCV therapy in the liver transplant setting: Is there a point of no return? 11:03
Marina Berenguer, Valencia, Spain

HBV in liver transplantation - is this the end of the road? 11:21
James Fung, Hong Kong, Hong Kong

HCV positive donor for negative recipient 11:39
Elisabeth C. Verna, New York, United States

T cell exhaustion and post liver transplant viral infections in the clinic 11:57
Xian Chang Li, Huston, United States

Featured Symposium
10:45 - 12:15 Auditorium 8

The power of imaging - radiology and pathology

Chairs:
Yu Fan Cheng, Kaohsiung, Taiwan, Republic of China
John Lake, Minneapolis, United States

The impact of imaging and histopathology on steatotic liver graft selection - the surgeon’s view 10:45
Darius Mirza, Birmingham, United Kingdom

Updated imaging modalities in liver transplantation in treatment of HCC 11:03
Yu Fan Cheng, Kaohsiung, Taiwan, Republic of China

The role of dual-tracer PET/CT with 11C-acetate (11C-ACT) and 18F-FDG in liver transplant for patients with HCC 11:21
Tan-To Cheung, Hong Kong

Oncological outcomes - the view from pathologist 11:39
Mina Komuta, Brussels, Belgium

Evolving role of SBRT for bridging HCC patients awaiting transplantation 11:57
Laura Dawson, Toronto, Canada
Scientific Programme

Sponsored Lunch Symposium
12:30 - 14:00
Auditorium 2

Sponsored Workshop
For more details, please visit the <a href="https://2018.ilts.org/industry-program.html">2018 Joint International Congress of ILTS, ELITA & LICAGE website</a>

Others
12:30 - 13:30
Restaurant CCL

Woman in LT lunch gathering

**Summarizing the results of our survey**
Gabriela A. Berlakovich, Vienna, Austria
Marieke Van Rosmalen, Leiden, Netherlands

**Summarizing the recent published articles on women and academic career**
Elizabeth Pomeret, Denver, United States
Norah Terrault, San Francisco, United States

**Interview with ILTS & TTS presidents - Patrizia Burra & Nancy Ascher**
Patrizia Burra, Padua, Italy
Nancy Ascher, San Francisco, United States
Nazia Selzner, Toronto, Canada

**Round table**

State of the art lecture
14:00 - 14:30
Auditorium 1

State of the Art II

**Chairs:**
Catherine Paugam-Burtz, Paris, France

**Critical Care Management of Acute Liver Failure**
Alistair Lee, Edinburgh, United Kingdom

Concurrent Oral Abstract Session
14:45 - 16:15
Auditorium 2

Acute Liver Failure

**Chairs:**
Scott Nyberg, Rochester, United States
Didier Samuel, Villejuif, France

**O-089 Prognosis of ALF of unknown cause: results of the French multicentre prospective HASIPRO study**
Coilly Audrey, Villejuif, France
### Scientific Programme

#### O-090 Development and validation of FLF-transplant score to predict mortality of status 1A candidates
Zhiyong Guo, Guangzhou, China  
14:55

#### O-091 Validation of the ALFED score in predicting outcome in hepatitis A induced acute liver failure
Shabala Paul, Kochi, India  
15:05

#### O-092 CHI3L1 protects TAA-induced liver injury via regulating STAT3-mediated T cell differentiation
15:15

#### O-094 Albumin dialysis with MARS® in the treatment of patients with acute liver failure (ALF) in the real life: a large cohort from two centres
Saliba Faouzi, Villejuif, France  
15:35

#### O-095 Artificial liver support in patients with acute liver failure: a single center experience
Eva Kieslichova, Prague, Czech Republic  
15:45

#### O-096 Indications for liver transplantation in patients with severe liver dysfunction/acute liver failure related to exertional heatstroke
Didier Samuel, Villejuif, France  
15:55

#### O-097 Reversible causes of acute liver failure: acute Budd Chiari syndrome, rescue with endovascular therapy
Rajiv Lochan, Bangalore, India  
16:05

---

**Concurrent (LICAGE)**  
14:45 - 16:15  
**Auditorium 3**

### LICAGE Parallel Session I: Progress and challenges in perioperative management

**Chairs:**  
Claus Niemann, San Francisco, United States  
Koen M.E.M. Reyntjens, Groningen, Netherlands

<table>
<thead>
<tr>
<th>Topic</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEE: must have or only when indicated?</td>
<td>14:45</td>
</tr>
<tr>
<td>Dmitri Bezinover, Hershey, United States</td>
<td></td>
</tr>
<tr>
<td>Fast tracking revisited: more than just extubation</td>
<td>15:07</td>
</tr>
<tr>
<td>Gianni Biancofiore, Pisa, Italy</td>
<td></td>
</tr>
<tr>
<td>The recipient of a marginal-liver - perioperative challenges</td>
<td>15:29</td>
</tr>
<tr>
<td>Annabel Blasi, Barcelona, Spain</td>
<td></td>
</tr>
<tr>
<td>How low can you go? Managing perioperative hyponatremia</td>
<td>15:52</td>
</tr>
<tr>
<td>Constantine Karvellas, Edmonton, Canada</td>
<td></td>
</tr>
</tbody>
</table>

---

**Concurrent (LICAGE)**  
14:45 - 16:15  
**Auditorium 4**

### LICAGE Parallel Session I: Progress and challenges in perioperative management

---
Alcoholic liver diseases / NASH / NAFLD

Chairs:
Kymberly Watt, Rochester, United States
Giacomo Germani, Padua, Italy

O-098 Targeting fatty acid oxidation protects fatty graft against ischemia-reperfusion injury in liver transplantation
Yan Xue, Hong Kong, China

O-099 Donor PNPLA3 rs738409 genotype is a risk factor for graft steatosis. A post-transplant biopsy-based study
Denisa Erhartova, Prague, Czech Republic

O-100 Aldose reductase promotes steatohepatitis in mice through regulating inflammatory response and lipid metabolism
Chang Xian Li, Nanjing, China

O-101 An effective defatting cocktail to reduce liver graft steatosis before transplantation
Lynda Aoudjehane, Paris, France

O-102 The distribution of coronary artery disease among patients with cirrhosis undergoing protocolled coronary angiography
Chandra Bhati, Richmond, United States

O-103 Effects of the share 35 policy on liver transplantation outcomes for patients with NASH: an analysis from UNOS database

O-104 Early liver transplantation for severe acute alcoholic hepatitis: pilot program in a single transplant centre in Italy
Giacomo Germani, Padua, Italy

O-105 Outcomes of living donor liver transplantation for severe alcoholic hepatitis confirmed by explant histology: a single center experience of 39 patients
Narendra Singh Choudhary, Gurgaon, India

O-106 Living donor liver transplantation for alcoholic liver disease: the North American experience
Hillary Braun, San Francisco, United States

Outcomes / Complications

Chairs:
David Victor, Houston, United States
Gabriela A. Berlakovitch, Vienna, Austria

O-107 The AKI-predict-score: a new prediction model for acute kidney injury after liver transplantation
Marit Kalisvaart, Birmingham, United Kingdom
## Scientific Programme

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Author(s)</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>O-108</td>
<td>Short- and mid-term outcomes of left split liver graft in Europe: a report from the European Liver Transplant Registry (ELTR)</td>
<td>Roberta Angelico, Rome, Italy</td>
<td>14:55</td>
</tr>
<tr>
<td>O-109</td>
<td>Early allograft dysfunction (EAD) following liver transplantation (LT): outcomes up to 10 years in 2,008 consecutive liver transplants</td>
<td>Burcin Ekser, Indianapolis, United States</td>
<td>15:05</td>
</tr>
<tr>
<td>O-110</td>
<td>PrePro trial: a randomized double blind placebo controlled trial to analyze the effect of synbiotics on infectious complications following living donor liver transplant (LDLT). [CTRI/2017/09/009869]</td>
<td>Shweta Mallick, Kochi, India</td>
<td>15:15</td>
</tr>
<tr>
<td>O-111</td>
<td>The outcomes of adult liver transplant recipients in Korea using Korean network for organ sharing data</td>
<td></td>
<td>15:25</td>
</tr>
<tr>
<td>O-112</td>
<td>The impact of new-onset diabetes mellitus after transplantation (NODAT) on outcomes after liver transplantation: the largest non-registry study</td>
<td>Aloysious D Aravinthan, Nottingham, United Kingdom</td>
<td>15:35</td>
</tr>
<tr>
<td>O-113</td>
<td>Donor hepatectomy time in donation after circulatory death donors is an independent risk factor for development of biliary strictures and early graft loss after transplantation</td>
<td>Marjolein van Reeven, Rotterdam, Netherlands</td>
<td>15:45</td>
</tr>
<tr>
<td>O-114</td>
<td>Deciphering the molecular basis of new onset diabetes after transplantation: a systems biology approach</td>
<td>Mamatha Bhat, Toronto, Canada</td>
<td>15:55</td>
</tr>
<tr>
<td>LB-001</td>
<td>Potentially life-threatening complication for living liver donors: Near-Miss Events</td>
<td></td>
<td>16:05</td>
</tr>
</tbody>
</table>

---

### Concurrent Oral Abstract Session

14:45 - 16:15  
**Auditorium 8**

### Pediatrics

**Chairs:**
- Paolo Muiesan, Birmingham, United Kingdom
- Mohamed Rela, Chennai, India

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Author(s)</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>O-115</td>
<td>Effect of graft size matching on pediatric living-donor liver transplantation at a single center</td>
<td>Jinzheng Cai, Tianjin, China</td>
<td>14:45</td>
</tr>
<tr>
<td>O-116</td>
<td>Catch up growth after liver transplantation in children with biliary atresia</td>
<td></td>
<td>14:55</td>
</tr>
<tr>
<td>O-117</td>
<td>Improving long term outcomes following paediatric liver transplantation: results from a service for young people in New Zealand</td>
<td>Rachael Harry, Auckland, New Zealand</td>
<td>15:05</td>
</tr>
<tr>
<td>O-118</td>
<td>Portal vein reconstruction - technique, outcome and risk factors for early thrombosis in pediatric living donor liver transplantation (LDLT)</td>
<td>Thiagarajan Srinivasan, Gurgaon, India</td>
<td>15:15</td>
</tr>
</tbody>
</table>
Scientific Programme

O-119 Living donor liver transplantation is associated with improved long-term patient and graft survival in children in comparison to deceased donor liver transplantation
Mohit kehar, Toronto, Canada

O-120 Evaluation of graft fibrosis in long-term follow-up of paediatric liver transplant: comparison of METAVIR and LAF score

O-121 Ten-year protocol liver biopsy from asymptomatic children with normal biochemical liver function test and graft histology

O-122 Experience with combined liver and kidney transplantation for primary hyperoxaluria type 1 with special reference to risk for hepatic artery thrombosis
Alexandre Darani, Chicago, United States

LB-002 Impact of graft type in paediatric liver transplantation: a single center experience
Roberta Angelico, Rome, Italy

Poster Sessions
16:15 - 17:00

Poster Session: Surgical Videos 5

eP-013 Portomesenteric shunt for liver transplantation and complete portal vein thrombosis
Xiangcheng Li, Nanjing, China

eP-014 Living donor liver transplantation for abernethy malforation and severe hepato-pulmonary syndrome
Palaniappan Kumar, CHENNAI, India

eP-015 Totally laparoscopic living donor right hepatectomy in bile duct anomalies
Heon Tak Ha, Daegu, Korea, Republic of

eP-016 Coronary vein to portal vein anastomosis for the recipient with small portal vein and large coronary vein in living donor liver transplantation
Koji Natsuda, Seoul, Korea, Republic of

Poster Sessions
16:15 - 17:00

Poster Round II, Session 2

For a complete list of posters please see Poster Round II, Session 1:

Click on Poster Round II, Session 1, taking place on Friday, 25. 05.2018 10:00-10:45.

Viewing Sessions of Poster Round II, are:
Session 1 - Friday, 25. 05.2018, 10:00-10:45
Session 2 - Friday, 25. 05.2018, 16:15-17:00
Session 3 - Saturday, 26.05.2018. 10:00-10:45
Late Breaking Oral Abstracts I

Chairs:
Daniel Maluf, Charlottesville, United States
Albert Chi Yan Chan, Hong Kong, Hong Kong

LB-003  Overall donor and recipient risk and not retrieval practice impact on outcomes after DCD liver transplantation - a comparative analysis between retrieval centres in UK
Amanda Pinter Carvalheiro da Silva Boteon, Birmingham, United Kingdom
17:00

LB-004  Expanding the pediatric donor pool: use of CDC high risk and donation after cardiac death livers
Dev Desai, Dallas, United States
17:10

LB-005  Effect of everolimus plus reduced-dose tacrolimus in de novo living-donor liver transplantation recipients on recurrence of HCC: 24 months subgroup analysis from the H2307 study
Arvinder Singh Soin, Gurugram, India
17:20

LB-006  An open-label proof-of-principle phase 2a study to evaluate autologous hematopoetic stem cell transplantation for allogeneic organ transplant tolerance (ASCOTT)
Andrzej Chruscinski, Toronto, Canada
17:30

LB-007  Peak Workload Index during cardiopulmonary exercise testing as predictor of length of hospitalisation following liver transplantation
Katyaayani Katayayani, London, United Kingdom
17:40

LB-008  Pre-transplant serum creatinine as a predictor of the development of chronic kidney disease at one year after liver transplantation in patients with a nephroprotective immunosuppression
Jonathan Aguirre, Barcelona, Spain
17:50

LB-009  Moderate-to-severe new-onset metabolic disorder (sNOMD) associated with the poor prognosis of liver transplantation may be predicted by FMO3 and MELD score
Yuan Liu, Shanghai, China
18:00

LB-010  Analysis of risk factors affecting the development of infection in artificial vascular grafts used for reconstruction of middle hepatic vein tributaries in LDLT
Sami Akbulut, Malatya, Turkey
18:10

LB-011  Liver registries in Poland. Numbers, trends and results of deceased liver transplantation in HCC, HCV and HBV recipients
Jaroslaw Czerwinski, Warszawa, Poland
18:20
Late Breaking Oral Abstracts II

Chairs:
Goran Klintmalm, Dallas, United States
Hu Zhenhua, Hangzhou, China

<table>
<thead>
<tr>
<th>LB-012</th>
<th>Validation of a model to predict renal recovery after liver transplantation</th>
<th>17:00</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Goran Klintmalm, Dallas, United States</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LB-013</th>
<th>Non-alcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma listed for liver transplantation in United States: data from the Scientific Registry of Transplant Recipients</th>
<th>17:10</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Zobair Younossi, Falls Church, United States</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LB-014</th>
<th>Down-regulation of miR-152 contributes to the progression of liver fibrosis via targeting Gli3 in vivo and in vitro</th>
<th>17:20</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>LB-015</th>
<th>Curative correction of FAH deficiency by chimeric stem cells transplantation</th>
<th>17:30</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Erik Nelson, Rochester, United States</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LB-016</th>
<th>Hyperglycemia-triggered ATF6-CHOP pathway modulates inflammatory responses by β-catenin signaling in liver ischemia/reperfusion injury</th>
<th>17:40</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Jianhua Rao, Nanjing, China</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LB-017</th>
<th>IL-17 activates the IL-6/STAT3 signal pathway in the proliferation of hepatitis B virus-related hepatocellular carcinoma</th>
<th>17:50</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>LB-018</th>
<th>Protection of steatotic livers through the preservation of the endothelial glycocalyx and the formation of nitric oxide</th>
<th>18:00</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Alexandre Lopez, Villejuif, France</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LB-019</th>
<th>Small-for-size grafts increase recurrence of hepatocellular carcinoma in liver transplantation beyond Milan criteria</th>
<th>18:10</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Eung Chang Lee, Goyang, Korea, Republic of</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LB-020</th>
<th>Results of LITMUS (NCT 02541916): the liver immune tolerance bio marker utilization study</th>
<th>18:20</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Andrzej Chruscinski, Toronto, Canada</td>
<td></td>
</tr>
</tbody>
</table>

Anesthesia / Critical Care Medicine Interactive Cases

Chairs:
Terry Pan, Singapore
James Findlay, Rochester, United States

<table>
<thead>
<tr>
<th>Interactive Case Presentation I</th>
<th>17:00</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sonali Joshi, San Francisco, United States</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Interactive Case Presentation II</th>
<th>17:30</th>
</tr>
</thead>
<tbody>
<tr>
<td>Natalie Smith, New York, United States</td>
<td></td>
</tr>
</tbody>
</table>
Scientific Programme

Interactive Case Presentation III
Faouzi Saliba, Villejuif, France

Concurrent Oral Abstract Session
17:00 - 18:30
Auditorium 4

Anesthesia / Critical Care Medicine Interactive Cases

Concurrent Oral Abstract Session
17:00 - 18:30
Auditorium 6

Pathology/Radiology

Chairs:
Jimin (Nancy) Liu, Oakville, Canada
Deniz Balci, Ankara, Turkey

O-123 Normothermic regional perfusion rescues ischaemic injury to the biliary tract and reduces ischaemic cholangiopathy in DCD liver transplants
Maithili Mehta, Edinburgh, United Kingdom

O-124 Baskent University expanded criteria for hepatocellular carcinoma (HCC): the importance of the histopathological features as a part of the evaluation criteria for liver transplantation
Gonca Ozgun, Ankara, Turkey

O-125 Telepathology in liver biopsy for transplant: the value of smartphone and microscope adapter for real-time expert evaluation
Natalie Bath, Worcester, United States

O-126 The outcome of children receiving macrosteatotic grafts from their parents
Rie Irie, Tokyo, Japan

O-127 Percutaneous transhepatic bilioplasty with placement of biodegradable biliary stents for treatment of post-liver transplant biliary anastomotic strictures: a single centre prospective study

O-128 Combination of hepatic R2* and 1H MR spectroscopy in quantification of acute cellular rejection post liver transplantation
Hsien Jen Chiang, Kaohsiung, Taiwan, Republic of China

O-129 Diffusion-weighted imaging for predicting outcome in liver transplant patients with hepatocellular carcinoma
Yi-Hsuan Chuang, Kaohsiung, Taiwan, Republic of China

LB-021 The value of intravoxel incoherent motion (IVIM) for hepatocellular carcinoma grading at explant
Nagihan Inan, Istanbul, Turkey

LB-022 The value of imaging findings for predicting hepatocellular carcinoma (HCC) recurrence after living donor liver transplantation (LDLT)
Sadik Server, Istanbul, Turkey
Scientific Programme

Concurrent Oral Abstract Session
17:00 - 18:30

Auditorium 7

Viral Hepatitis / Basic Science
What's next after viral hepatitis?

Chairs:
Murat Dayangac, Istanbul, Turkey
Helena Miranda, Porto, Portugal

O-130 Changes of indications for liver transplantation in the era of direct acting antiviral therapy in Europe
Giovanni Perricone, Milano, Italy
17:00

O-131 Intentional transplantation of hepatitis C positive livers into hepatitis C negative recipients - first reported case series in the English literature
Paulo Martins, Worcester, United States
17:10

O-132 The paradox between allocation and outcome using HBsAg positive livers
Lucio Caccamo, Milano, Italy
17:20

O-133 Glycogen synthase kinase 3 beta regulates liver inflammation activation and resolution by controlling AMPK activities
Haoming Zhou, Los Angeles, United States
17:30

O-134 Scaffold-free 3D-bioprinting (3DBP) of the liver and its continuous perfusion with the bioreactor
Burcin Ekser, Indianapolis, United States
17:40

O-135 Decreased expression of pigment epithelium-derived factor is associated with increased CD36 and lipid accumulation in non-alcoholic fatty liver disease
Kuang-Tzu Huang, Kaohsiung, Taiwan, Republic of China
17:50

O-136 hEPCR.hTBM.hCD47.HO-1 contributes to increased survival, reduced platelet sequestration and modulation of coagulation activation in GalTKO.hCD46 porcine livers perfused with human blood
Arielle Cimeno, Baltimore, United States
18:00

O-137 Stereotyped molecular response during liver and kidney ischemia/reperfusion injury
Sai Vineela Bontha, Charlottesville, United States
18:10

O-138 Superiority of multiple random gene sets in predicting survival of patients with hepatocellular carcinoma
Timo Itzel, Mannheim, Germany
18:20

Concurrent Oral Abstract Session
17:00 - 18:30

Auditorium 8

Surgical Videos for Technical Innovation

Chairs:
Xiangcheng Li, Nanjing, China
Pal-Dag Line, Oslo, Norway

O-139 Robotic living donor right hepatectomy
Gi Hong Choi, Seoul, Korea, Republic of
17:00
Scientific Programme

O-140  ‘Rex’ mesenterico-left portal vein shunt for late portal vein thrombosis after pediatric living donor liver transplantation
Mettu Reddy, Chennai, India  17:15

O-141  Hybrid split deceased donor liver transplantation for two adult recipients
17:30

O-142  A novel technique for collateral interruption to maximize portal venous flow in pediatric liver transplantation
Seisuke Sakamoto, Tokyo, Japan  17:45

O-143  Our technique of dual graft living donor liver transplantation
Venugopal Kota, Chennai, India  18:00

O-144  Pure 3-dimensional laparoscopic extended left hemihepatectomy as a living donor for living donor liver transplantation
Kyung-Suk Suh, Seoul, Korea, Republic of  18:15
Scientific Programme

Saturday, 26 May 2018

Vanguard Sessions
06:30 - 07:30  Restaurant CCL

Vanguard Surgical Video Sessions

Chairs:
Arvinder Singh Soin, Gurugram, India
Yaman Tokat, Istanbul, Turkey

Procurement technique for abdominal multivisceral transplant  06:30
Akin Tekin, Miami, United States

Technique for split liver-- in situ and bench split  06:45
Dieter Broering, Riyadh, Saudi Arabia

Complex bench reconstruction in LDLT  07:00
Prashant Bhangui, Medanta, India

Right lobe LDLT implantation technique  07:15
Deniz Balci, Ankara, Turkey

Plenary Abstract Session
08:00 - 10:00  Auditorium 8

Plenary Abstract Session II

Chairs:
Nigel Heaton, London, United Kingdom
Elizabeth Pomfret, Denver, United States

O-145  Suppression of mitochondrial biogenesis after partial liver transplantation in mice: role of TGF-β signaling and miR23a  08:00
Zhi Zhong, Charleston, United States

O-146  Cell-free DNA and miRNAs correlate with early allograft dysfunction post liver transplantation  08:12
Sai Vineela Bontha, Charlottesville, United States

O-147  Different injury of common bile ducts in donation after circulatory vs brain death: histological and immunohistochemical evaluation  08:24
Francesca Tinti, Rome, Italy

O-148  Robotic living donor right hepatectomy: short-term outcomes compared with conventional open donor hepatectomy  08:36
Gi Hong Choi, Seoul, Korea, Republic of

O-149  Can hypothermic oxygenated perfusion rescue futile DCD liver grafts?  08:48

O-150  Liver transplantation for colorectal liver metastases at 10 year follow up  09:00
Jon Magnus Aa Solheim, Oslo, Norway
Scientific Programme

O-151  
TLR4 mediated intestinal microfold cells reduction was required for invasive fungal infection after living donor liver transplantation  
Jiang Liu, Hong Kong, Hong Kong

O-152  
Novel combination of 3D printing, virtual reality and indocyanine green fluorescence to assist the in-vivo procurement of a monosegmental graft in living-donor liver transplantation  
Yi-Ting Yeh, Taipei, Taiwan, Republic of China

O-153  
Improved survival after liver transplantation in children with hepatopulmonary syndrome

LB-023  
Liver transplantation: long-term data from the European Liver Transplant Registry  
Vincent Karam, Villejuif, France

Poster Sessions
10:00 - 10:45

Poster Session: Surgical Videos 6

eP-017  
Hybrid 3D laparascopic right lobe donor hepatectomy - first series from South Asia  
Thiagarajan Srinivasan, Gurgaon, India

eP-018  
Peeling off technique in liver transplantation in patients with stents after tips  
Xiangcheng Li, Nanjing, China

eP-019  
Orthotopic piggyback liver transplantation by side-to-side caval anastomosis

eP-020  
Liver transplantation for advanced hepatocellular carcinoma combined with portal vein tumor thrombus  
Ke Wang, Nanjing, China

Poster Round II, Session 3

For a complete list of posters please see Poster Round II, Session 1:

Click on Poster Round II, Session 1, taking place on Friday, 25. 05.2018 10:00-10:45.

Viewing Sessions of Poster Round II, are:

Session 1 - Friday, 25. 05.2018, 10:00-10:45
Session 2 - Friday, 25. 05.2018, 16:15-17:00
Session 3 - Saturday, 26.05.2018, 10:00-10:45
The 2018 Annual ILTS Meeting,
May 23-26, 2018,
Lisbon, Portugal

**Scientific Programme**

State of the art lecture
10:45 - 11:15  
Auditorium 8

**State of the Art III**

**Chairs:**
Patrizia Burra, Padua, Italy

- **Utility of prognostic models in patients awaiting liver transplantation**  
  Patrick Kamath, Rochester, United States  

The best of ILTS
11:30 - 13:00  
Auditorium 8

**Best of ILTS**

**Closing remarks**

- **Best of ILTS - Hepatology**  
  Patrizia Burra, Padua, Italy  
  11:30

- **Best of ILTS - Surgery**  
  Mohamed Rela, Chennai, India  
  11:55

- **Best of ILTS - Anesthesia**  
  Ryan Chadha, Jacksonville, United States  
  12:20

- **Closing Remarks**  
  12:45